var title_f16_19_16688="Diagnosing APVL";
var content_f16_19_16688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 612px\">",
"   <div class=\"ttl\">",
"    Considerations in diagnosing acute persistent visual loss*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 592px; height: 532px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These are considerations only. Clinical picture must otherwise fit.",
"     <br/>",
"     &Delta; While corneal abrasion and keratitis are most common in patients who wear contact lenses, other sources of acute persistent visual loss should be considered if findings do not confirm abrasion or keratitis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16688=[""].join("\n");
var outline_f16_19_16688=null;
var title_f16_19_16689="Sequestration ultrasound";
var content_f16_19_16689=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sequestration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 380px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF8AXwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDD03XfC8bIHuTD6k12kGpeA7y02f2snnY676+Zrm31ZVK3OjSZ/wB01nxW67/9IsJYj7ZFAH0x/ZPh26V2t9WDHoP3lZ9zoVpbgmHUAy+xrw+zjWH5oWljHXG41pwa5NbqAJHb6mgD0O5sdI8z/TbllOOvtVaVtNsImOl36McdO9csNd+1ReXKqEHuabaafDcMz79h6jBoA0bm+v7g7VmAB71Po2jXMkrSS3Ck+uaZapZbPKZ5GkHpUU6rAGG6ZfTmgDQ1JNiskl0oUdcNWOlwkb/6NcksPesW6ZBIcktz1LGmM8ca5jIUnqaAN6a/ncfvLhfoRzTbZFdWLtkHqc1jLLCR++Zm78U0SxlshmRV96ANny1PEKhmzT5YpYwHnTatZtnNHE28XJH1rRbVYZjieTzI17DvQAyGXzC2znFWjFfzL9xPLA6mqEmooXP2eDalQy3t1MQiy7V9KALkyLG4890PqijkUSQrIytECqd8moI4LgLkFB71PBpf2jmW4w3scUAVb15bfiE5z71R33UjnIbn3rqYfD9ssiZkZyfU1dfS7SKZY2Ax0yKAOKmgvJ1ACDA96rJpd/uJ2sfpXqK6Na2sJkiTdkfeY8Cs15VhjcQqGagDiodIvyP3rBF7571N/Y0oXcrAqOSa1vMllu2+0EhM5wKsTtK0TJbRg0AY1tcR24KM2CKhuZmnmwu0pmpIdEvLmZmK4BNOutFmgQjHSgCaMwogXCk+1WFFug82UAVzzM9pINscjtjk44qG+1GV4sGGT8qAN+XWbeLcIEP1rPbU2kc7UXI54rFhu3dNpgbp1xUsLeU24KRnjmgC+7y3UgLDAokAjcc9KsxTK0QVV5qF0XJ3hjQAm0SnKAEikU7WxJjFTKNqgImO1SvDbgqWYmQ9j0oAVChXdkbRTE8ydsRbwg9Kk8uPhY+D6VNB5ynYrBB34oAlhhS3AZm596NonYMhCjNVJgWm2SMzj1FXIvugeWVA9KAJNj+escPzM3BI7VeOn/ZlD3DIWPrVUFkRmtxtY/eJqNFkaQJcO80jdB2oAuSXsUaH7PbBs+oqB/tEiA3L+TEv3VXvVqS2a1CtIxA7CiUebGdyAg/dzQBXt57eP/URGRvWmTytO+1l2rT3jNog8nqetQL5sg+Y7c0AJI0CkJuJI9KaSjDALVG9r5Mgb7xbkU6VmRQQgz6UAOlhyoYgKoqLY55WbiiMSyKTI3ymlEMajG5qAO5T4w6NMw36WjBuuQOKivvFGhaohaHTUUn0WuEXwTrkKsi2DSe+ytTSvC+sWro9xE0aD+ErQBS1v7MxJjt2jX/dxWMTA0f3c+9d5rFsEhX7RIoXHIK1y2pafDLETbToFx0FAGAdgbILD6VoaekjHdE0meuMVkXG60XaW3HNX9J8TmzYIYlOe+KAOkto5I/ndGVvUiprq+86Py3AJHc1iz+JLmXpjae2KhS5uZ33fKTnpQAmoQbjuXtzWVIm6UK7ELXd6LbSTxsJ4UK45rl/F+nCOUmIMgHOBQBJY29kn+smBPpmum0ax0NyDesSvfFeVsHVv9YwPan2st70MzbD6HrQB7iPDHh28A+zsOexNTf8IBpwjJikVfxrxmK5vkx5MswI/wBqtaxv9VkG2W5uAT/tGgD06XwFYxxK8moxxgdRuFQP4d0G1IBvfMk9jXJWlnd3HzTXMuB6mpJo/KwIy7yZxmgDpZYNLjGBMOOxrPuoBtL22GXtipNN0aS6QGXgHuav22kOs6xJdBEHUnpQBFpkF1IBvjUL71vQ21oId1ymXXsOazrhpbGRRHL5/qFWtG1F1fqohtnDHrlcUAc34o1qOJDFbrJt6YIxXJwapcB8EEKTXo2t+HXS2kkuYwr46k1xKaWtvcrJJIpA/hzQBBLehSGIJNWLLVypJEbAdM4qS51C2RcLbqT64qk+rSCNljtlH1oA27fW7VZ1MmQO9dTbaloM8K+aoLEdO9eQ3EzXLgsAnPapITJHNiOQsaAPZFn0CXaqQRH6gVQ1pNHACRW0ZJ9BXA2UUkhyk5EueldBZ+GtZuSJo3LigCK80lJFzaxIo9xXN39mIZdrBdw54r02z02/trcrdWzYxgsR3qGDQLCRjc30ioR/CaAPKC1yH2wxHGfSlM86SAPGfc4r1WWwsEjfyinzfdrmtTshAp2xhge9AHNxhpgcsqjHHNKlgojaSWQlh0NR3cDb/wB22Cf4fSqtzNJbwbZmOKALUbRwcLlmPep0WQ/N2NY9leIW3t90Vs206XEg5O3sBQBbtxs+aNAX96nkdyOO/pTZAUI6KPU1G95I4WKxj81jxkCgCxDkAiQ4BHSpbERQyM27dKfuk9qdDol6yia7DAdQKdJaqpxtcY70AOu5jI6tJgoO1I06TugXCqvT3qN4Y4yoTc0p6k/dqzb6YZZGYNkD06CgBwto9m+Rh9M1nvBm582Q7Y/StG4SCE4mfgdqz5bv7a+y3jPljuaAJp2gjTdEMk9M1kXM5Dc9+1T3EjxNjIIXjFRW8CyuXmB20AS21u92oC/KvvWktmFUA9qpK4hfaj8VN9sXu3NAH1BbX8aRBvs8LKfar8cul3EX7+3jz6YFeI6f4s+z/J56FPQtWna+MI/PDblP40AeiapoWg30DM9mh4P8Nefav4L0IkmCPyz6AYrf03x5CZRE0UbZ6ZPBrQ1PV7SeDe8EKkj+EigDybV/BulNbN8o3CuEvfD1pAx2gEg8Yr1jWLq2lDbBH6ferF0/w3/aspcTW6p6hulAHmZ0vajPvx6A0tjHtl6ZPqa95tPg9Z6lCHOrxox7bhVDWPgjDAhddejXA/vCgDzXTllBJjlAPXA70atay3EBMkak+tb114S0/Qid+rC5YclVbOao3eoWiQMiQv7FqAPMtU0+SOU9N3XFQbWjjGYzkdwK6x1+2ysI4/mz25p50m627Qqc9jQBhacI0IYqSfQ101nJaTEKVCOO9Pi00Qw5ugi49Kzb+CNlJtXwB6UAaU6tExMbEp7GnR3yJIgGN5OPm6VgQXF2ilEkDDvzTGguZzmRtrdj6UAesaDZh4BLdXyKp6KDXT2M/hmygJvpkdz714bHp1wVBfUgOOm+po7cIMvL5zL0+bIoA9muPGXhmzVlsbLzpOx25rmNY+Id+wKWFgsIHTArjYrh41yoRMd6tW9/NJwFSQ9zmgCjqGvazqUjfaHIHTAqvbq7YMr9PerNz54kYlEVc9QajLwMm0qRJ60AVLpFGc8Y6Yp1vZmWEmWQKtPaCWIb2AZewNQbZ5m4wieh6UALc6am0C3LOfXNU4dNuftQwcYrctoRCg3zKCfQ0jpO826IgqO9AEunoI50SRQ0me1e1eEb63t7RTKE4HSvFltJ5FaQNhgOoqmmo32nTgPeMyf3QaAPpS6uINStii7FB9K5/UfCK3q5iBJx+BrzPRfHqRMI5GJwPWuy0n4kFWCogKngE0AZ1x4UuLOR/MDH0HaoI9Ca4QrO5T8e1dfdeK5L+PaLdAT/ABVyGqzzmUsHz7A0Ac9rOkWWlybxIXbPc1yOs+Xdj5EGPautuYlu5v8ASJFBz0zzWbeaOAWaI4UetAHHtbCH5doI9qvWUkkKfu7difp0qybfbcHb81WQLhV4dVUUAXtC0qXUbkPqkwht/Y4Nddcar4b0O18qzRHlHc8nNeXajdXFwxjWdgv+yayZcxjG5mPqTQB6VL4xjcclcDsKrjXGvTi3hGPXFecwTRLJmR/wzXU6V4htoEEcahT6mgDQiS6ub3ZIQqn+FeldBK7WdoltApaRu9Ylvr1pvyu0v6g1u2F9DOdxwD6mgDKuNLuJQDK2CadZ2flyCMSZz/drWvXiAMjOXPZVqDS457i5DmNYkHrQBBcaPFGTIx47+9Zjn5yEIVRV7xPcNGCsb8j0PWuetVnu5FWRvl9RQBamiQyCRmAHpT82o9TVyTTomiAd9zD0rOe3COVB4FAF9bpQ5+VOPWrsF6MAnywPSuZkuYpGdQhBPpSru2DylLfU80AdVPrkartjUB/UVWuNV1Box++byj15rAtdPvL+QAI0a565robXR3jUJcytt7YoA0dJvbQR/vAZH6kt0o1LVNyhbNPLwf4Diuk0Dw3p8sQ89wq+p4pviDQdKtLcm3uoww96AOAub2/jO8X93Ef9lziq8utai3DancP7Fs1eurOSfKI3mem3pUcGmPDyIlbjkH1oAn0zV1QDzwsh7lhzVieT+022W6L+VU4TbQS/6TbhTn1zWmt/awRboYwreqigChcabPpqGSYKuR2rDuL6R2Ihck1rX1692NssjMKxrmzTduWUofagBJbh1jHmSnd6E01PMuV2oVUe1JHYRTSAyTE49au+XBCCYpAWA4AFAFa3s7eBw0rHI5NaEl1ZmMLEhJFZoPnPunDADoF4zVkJtXKRkL64oASaaCWPasYVzRp8M6vkKNoqOZ0jw5XgdD0pkGspAWAByexoA1bwPMFVUC468VA1pt2szlU7hKs2upW86/vFx9Kr3l9bAOE3UAR3MkQAFrITjqGqAyySIAI8v7VRF1ESxRCT71ZtLqRyABtx7UANe2vDNmcssZPArbtLWAQgMxI96pvNcOw80qyDpiiKZ7iTylOxaANCQWKqET5pM1PFBIgyFAU9qoXduloqkOGY+9SR3EzIC5OzHUd6AJZZZhlYlwp64rC1GyRsu5YGt1SQuScZ96o3Me+QquSPWgDlJ7XyzmNsE80Lez2wBEh4rUv4tqMQvIrnvOLSsXTB6c9KAOn0zxDe8bpSE+taf9uNN1cg1yMDBk4FTrHPKPlwAOmKAOshdJjuVwZD3rUGmv8AZ900/Dds152JZ4plGWwD1FdVpuroVRZpCQPWgDRksIolJDAmue1ppiNiggZ7DrW9BcW8k3zPwT2rVdbHyc4DN2zzQB5vY6bcSuScjPc1FqtitumwPuc12GowvsLAeWn+yMVy2oLhsuePWgDmpIJIsHGT61EZzEcvxWzL5UmFDkEVl3qAAqRu9KAI4dRw3BKGrkWsyIQfPc49Kw3hdTyBUkSnG0EjPWgDrbXxbIi4HzfWpo/GFzuAViFrkolVHx2PrVhxlMDFAHYPrkd0qmZua0rC6tmj+R/yNeayoQoZJDgdQTUlnfyRthScigD2C3jjig83cfxNVWuULH5R+Vclp+uPJGqSOWWuhhvofLXKA8UAYsceMybs5qyJ444wY5fn7isZJph+77VNFbyPKMjg96AOg0/xELfiVunYVtL4ltJ1T97tPq1ckNEjY72Y1NDpETcK3TpQB2MniKTydkUisp9DWFPd3FxMOHIz61lyaVdD/VP8o461uaHpu1QbhmJzQBcsdensmVAicccoK0ZJl1BfMmIyf7nFK+n2TLkHLCpo5Ft4W8uAnHfFAFMxaYiHzVY46sx6VXkvbKFWWCLeOxIqteapCsmZosHPSsnUtWMwCW8QVT3oAdLcqZy3y7j/AAikl82RlOxAvcUmk6fHK++aTk1euIY4n2sxK0AZd0XwBFGoI61HCHf7qgP3NaarC4IjjYmoXjWKQBAQaAKgid2+eUBh6dqupZ3RUFrn939KdHa7iW45q3b5t1Ik+YelAGfcx26IB5hdh1FVNsdwcLGox3xWo6WUkhaYlSewqhKI4nZbXPPegBBbtztIA9arrEyuRw4zzV2GKYYLtwfWpnIjXb5eT/eFADIbSOJBIwX6VFK2XxDGPwFaMbWxRTICKLq/to4CscX44oApQq6H5vm9QO1TR3MUKtuiJ+gqnDeZJKoeaWSZ3+Ux4BoAntZ7ea5HmNkZ7mtW4WKQrHG4CHuK5xo7eOXdGzb+4q9aEFgzMfUCgCxexGMczYUcClsJQYnQrkn+KkuV3DJGR6U+0vBGdiwcfSgDE1hfJQ4fcT2rnZFyCxUjHc1393El3yUAFclrMSxtsiOcHnFAGWlyFBUDGO9aNldFU45rPjjDdhmp0ZI8KqkHvQBrCZTGWePB6c0m6AQljjNV1kJQK5yO1Qtbu78MdtAGna3ilwVXIHFbdvqAjw5j4HrXOhUgg4PNWrK7iRAHOSe1AG9JqX2yQKUCp9KpappdtPAWjcA46UrXMZZAVAHtVozQrAVONx6UAcRHELW4fcoYDue1UNShM84ePp7V0WrW++Niqkk+lc7OzQ4Qgg0AZU0EgbjLCneX5acjk1bl5Ut0qss6scMKAI8b1G0801pSAFDHcavIYwOAKjcIzjAGaAIY0I+8Mk0k4ZcbUwPWpsYkGKlYAjmgCSzkEafIBjsal+1XPYnFUlmUMFH6VZWXjpQB1OraKmnTnZcLIR3BzUcHlyKB55UjjkYqnq8ZXcI5CB6g5rKil24Bdmx2PU0Adf8AZ7pY8wTpIMdDVEz3QYrtw/bFM8MxNcXQXzihJ4UnivTo/DSy26uPKZ/UUAcZYWuo3KqVglK98GuosbaaJAr2zg/7RrQjTU9MH7pUKdgKt281xdkGdCje/SgB9lo6SfvbghVHOAcVneI9Vit4Tb23lg/XmtPWpjBYkJgnHY15VfzmS7bzBls+p6UAF/IWctKQe+c1mb0EwIZyM9hVuSKKaQZcL+NatvbRRRAlSwHfigCfR1SQKUUvz908GtbUFaWEr9m2EDj1qna3cEKgBSPcdauprltACNjs3qw6UAZlrvgLDYQfeqtxNMhLeUWHritK71BZAXjUZPtVOG/upH8tIflHTIoArxSSMdzKU+tOtLiNXYSlvzpmqG5LjzyIk9Kp7XcZjxx3NAGuJ7POWiZvem/aIDLmKH86zoGu3O1Apx2q35lzGNrxLigAvriWZlWGIDHcUtu0qgLOOPSrMNyNuFjQsabIGkb53RPY0ARSTxDIaM56DFS2yWuC03zcfdp9ukitkbGHqasRWkbFnkAGPSgCkWAYmO3Hl/w1Mj2si4nIVsdKrSPm4eOIsOarzWbG4XzDg9c0AXoba1kkZkjIUdzVa7migmCxDe3bFS3LOECQyKFxWc8cobKlc+tAFqa4uMfPGAD0xVyzT90WmyPoazo7hThbl81p25jVeHBHoTQBaURRWzNjgjqa5e/svtBeRGAro79g1uI+hPQCsy+SOG22jgkc0AccY/JlIDE80+GGRnMgBCg96leIb2dck00XBA2jtwRQBdV/3ecoo6dKmgkBHJz+FZiyqzAHjnpWisoWIBAN1AEF1tjbBfJPOKsQWYMfmNIF79KYkCxHfMQW64NOuZZnjCxrgGgBWu4omyCzsPepLdpriQyO42jsKypIWijPmcMecUWTzHIRiFoA6+zmSRNrR5OOtc5rtpunZyoXHTFaul3LRrtbBIqLUroThgU5oA4m/wAiMgcA8cVTVAFGBg1tXqjdnHFZ8oAI44oAbGrkDpTyAoyetMWfB296lAHUnigBEGeR0ol+VeDg0EkZx07VG6ljyaAJIADhiQT61YAX1FV4wijAqTFAHo+tWOk7jHBKh981yt3Z2qkhJEBHTFJdyrGWXA4/OszcsjZZttAG1oMcYusFiOetd5ZTTIgEdzhPdq8vCgHKSncOmK1tJikuZkWR5evZjQB6vpc6SSjzbrOO1b11cwR2pZQCMc1zWgaZb2qLJMpkHqTVnXr+zjt9sKkcdM5oA5bWLqe5vSsZZYvQmsbUECgEEFqsXd3I28gHH0rG8q4vZf3R2j39aAIB/wAfHzHA9a0omdsBGJWqk+nzw8zMpPtVvSb+K3lEcgHpkigDTtUjXDylce/WlutSt0bZDG7seANvFaJ+zXcY8ryi3qadbu1qpRhFk9CF6UAVbC1uJ1MjRYU84pl4Jrf/AFaN9QK3bbUWjgYDb9SKx55Z7h3LXCqvpigCkIhKubks5PY0h0vA3xnavpmi4so0QSfajnqeahR9xCxyM+PegCRIpoWPlMCfWnCPzMm5l+b0Wq99LMiERqUrMFwVYFmO+gDZt18tjtSQjscU25EitueNip6cc062191RY8KfwxWnbata8tdKDjtQBlfamOEVCikdTUkIlc/eIWpLq5tL25zDlQPbipI1jA2q+AaAJPOitFH7ve5/iqlcGW7kzn5euBU08CQ8qTIW6DPSkBuIEyYsL2NAED2rZU4OBTXtHmbIO1RWvaxXt3EPLjEadyRmo76JbVf32+QjsOKAMmawUrudsY96S3i8x+AzAU2WQu3yoY09znNXLRpJF2wrgetAEm5Ldd2NxHY9qzr6ZLjLPAzY6AVYvbR94DzjntSTpNFb7VUY/vetAGHJNlSgg2Cs25RAOBg1dmaVZCZPWqVzH5oLN168UAJbKCeV+hq8i7CGJyKyVlkQqoPy5q3LcAKFjBLUAaKu0jcDNTrHOG+UDn1qvp10qJiTBftUsxnkYbGxn0oArahps8h3F8+wqqInt1wz4rdSBoYgz5J9zWLqEQlb7/FAD7VtrFhNx6VqRJ5sZbZu96wIlVGCx/jW7DcGK3CqQARQBh6oh3bdoFZUke3rWtfFpJcscis66dS21FOO9AFRVVSWxzSBjjf29Kdt/vHikGN2c0ALyefWlHTmlbaOe9MO48LQAoILYHanbyDjFRwoynOck08x5OcmgDZ1bEsrFWFZARvus+WJ4rQ86MghgSaoFCJvMC7j0+goA09OtzxuNdfo0QBUI6r7msHSgrRh2YK2OhrTty7SEbo8eyUAd3HE4h+e9TaR2NY88duJeb5GfPArEd5xwFLL7cVWnhEuMROH9c0Aad7HJGrMrpLn0NUIJZTJxEqfU1A9ndIgZ0kZR6VHHcQxMA8bhvegC9dNI2SwB47VDDbxSDMibT61P9tjCDbGSD3HWmw3SJJnyiQf71ACRQvbfNCd3fOa2NP1CdkKPCpPTNV7bUIYXwLVJGPpUtxdzkhoLdYh646UATzWk7MXlfYh7ZqS0s7NoyGcl/Ss9XZnHnysxPatFI/LTMBzIfWgCtd21oinZnzO2ap2+BONwCc/nVtRcxSZmKnP6VXuPKeUbshvagDVNt9qjKpt4FYzW0STskgXjrW3YKEtsl1wB1NZNzskkdgoJz2oAozRW6tgofqKYywoMqPqCelXid8JWaHCjvWDqAi5EZYUAa9tfWoj2LszWha3FtIMOyg1w6rKpxEpbPrV+2jnj+d1UCgDrLm33qHhcEdsURajDZpi7G7HrWTZ6jIsRXAx0FMuNHuNRXe8oRDz1oA34PGtmmUgtyvYE1S1HX31AhQiKo6kVn2Xhy4YrHFEJBn71bsPgWfG4yhSeduelAGVHcWh+V1LGtDTzCT8rBU9zikm8PTQP5SgMfX0qpc6C8Th7m43P2RTQBryrp6ndK4Y1JHFZ3Ckq/GOhrnpIJ0cLgkdhTnEyEIxKAnqKAE1nS0fd5HzH2rm5rZ1byz19K6zy1ghbM2SfWsK8l+csgDUAYFxA0LHd1PSnWkJJ8yRtvpVy43TNnaD9e1Ot41zhh+FACQPHG+VG41aW+Ebbj1Pao5UUYCYFOW13FckYNABNezz8LwtVZ48xk84rXW3sbdN0j7jTLpzLzHGNo6CgDGhUAAgYJ/WpY3LSbKqX7yI+enpUdg+5iS3zUAaM8WFzwaxplKyHiugW3UxZ31jX0AD8GgChKMjmmIARkikYsGIPSlViOMUARuSZAAOKkPyrn1pOc9OaXJzyOKAFUECnBWNLjJpQT60ATTHeM4wabafu5BuywFSzLkk9KghMglwSAtAHRaeIZGzGMNWtCjhPmUA/wB6szSWSJ0JPXHauu+wtd2+4Tqi/wC7QBz0U1wbjZCdw710OnWrl0aWME5z1qC2hhtXwZ48g9xWib8xxkl49uOtAGxeXdta2eGRM45FeaaxrMLXL5hHHQCpdf1xFLKX3ehzXHzXZmuOxBHrQB09vqJlT90hArQso5ppBiM4PUmuZtZECgiXbjkirlnqk9tcA73KZ4GaAO7t4Y9NTzDEHY+tIuplpCzW+5fQCodL123uUEdxCd3qeauqF8zdbEbT7UAMe/glICW2xu5IoeSHbwwUmteGyh8otcMu41RewtpJW+bAoAzH8tDtR97t0yasM0Yj+ZEGB1FUtUS3snxE4Zu2OaWwllMeZNu33FAEMlzcykxwD93nrjrViAuu2KVAM96ke4hV8R8v3wvFaVlBFOVkmU4HUHigCvdafJNDmP5Uxz71h/2fCxbzWC47Gut1ebFrtgkjjTHXcK4G7jnkvP3ZeQg8sOhoAuWkDCUrDFuA6Ein3j7flkCgd+KqyXF7CQnmiIevWm3KxrC3nz+azDtQBmXk5Rz5B47Yq5pZvbpQGkbaPSsdrYbzh2CjoPSup8MPHER5j8fSgDotKuri2h2oNij1qdtcuPmxIGx2qrqF7E6+WVIGOoFZ8UMQG9FY/WgC7NqF3dg5Plj1FVvLycyOT6kmnYUDczMpPAXFQzMYj+8Hy+9AFhxEiK2/cR09qQmKU5cgcUxby1MQCxEt3zxWfeX4fCwwndntQAXrF8pGML61lTtHaxkZLsf0rSjnCL++BB9MVTnuLfcQqZB6k0AY4lMjEEEe9Kkfltu3HP1qxcbC2UHFVWDHpzQA7ErZbdtH0qeIzsCBnHrUAJ6E5qzHI6rgHC+1ACTAW6bpRuJqS3vSyH+I+gFNUGd/3hyvvSJIkUmY0HFAFLUYpH/eFdorMs4x55xnrWxf3ZmbaxAPoKdYWSKm9uKALEIxCTnpWTeBpGJ52itYygttC/LVXUJFSLBXaP50AYEhIJwOlCtuGcVa2Bl3AcVERtPSgCPOXHYCnMc9BkUuzccAc0pQoMHigBirtXrk0vHemhucjlakBJ7frQBbk4/hqHYM+lPnVkkI6ilUZoA0tMkEYXJJ5rs7PV4Y7YK7ZbHSuGguRCvEQOKRrkzvu+ZfagDpNQvojKW8on6VQuL0TJtClR9aoG4fAUEmnoiOuWkUMOcUAZ2oQxMMuCfxrKwsZ/dR8d637mNXQgEH3rDnhlEh2E7fYUAKGcDgYqxDuLDJPFMjXIG7IPrjpVpEAHy5NAGpZXTRlcHFdhpF3LsDEhl9K4GMKWIcMfpWvpeoyWrBCpYE8UAeiw6haXDiKdCh9akvLWDyswuSp/hFYMc8dxArzABuxq7ptzNExaFBIvvQBVdLZHA+zSOe7Y6Uv2S0YbhJKmewNac+qS+W6/ZlDkVQgP3nmiIPtQBVWyR7gCCZ8Due9bEwKQbASz46HpU/gWTw4PFtsfF8c40eQGMFW2xpIeFaXHOzryOhwTxW38RfCM/gy7SKZpLrSLk4s74YJbuI3PQPjoejD3yKAPPntNpaSVA3PTNKt0I0CBVUeg7VJLKTlEG4DsxFQBWP3oSM0ASeXFMCNgLnnOM4qne6fHHGZHmCkc421Wvri6QmK3G3PesS7+0zPiR2+maALsX2Z5TmTcc88Vu2iIIx5KbTj71c/p1skbDcCxPaup0+GXAAG2PvmgB8MAIMkjgn0qKZnjlGZPkJzirV1NZxfLH8z+lUzJFJ8z8n0FAF2KaJsNH87KOhpspEh8y427R2plqJGUiKHYD3NVNRtkibJkZ2PYUALcTRXLBUUIo4qJ0ji5i69yaz3eVXxwBUpulkjEff2oAhkvMuQeQKiuEWdQV+UmpNpUlUiUk/xGkYRquJHG727UAVPszAEGQAVUuJFhOPMBNW5LNZQSJmAHP1rKngjEuMljQA5ZQ54qTzwBiiG1l2nyoyfcio3glVhuwGz0oAsI+9euBUM0wXCxncxoaEsuCaW3tUSTcMu1AEP2aZxu6GrCCVEwzVsR27yJkDaoHI9azr2Pa/QY9KAK9vKUfcz5FQX0hnlHPyipAjE56r6VDNnuML2FAEQbZxjiq7n5qlZsg4qBgfXmgBTnoPzoCb/lY4HrQCT0p2MjrQA11SMbV5xSDpU8UW8Ek49zUTEBiMA0ATnd1c0sQJbkj2ofOcGmlh+I9KAJ2JHAI4qFpdxOGI/Cm9BnBpE+eT5uKALliWZjucE+laE1vFEN6IWas0RKrbkfn61qWVwVCiRcjNAEcE7s20QKQe+Kux2fnNl1VParSTQHGAAT6VehtfOXK5570AY82jI4OzJPsKrpo1yCQiHFdILeaHO1hxTYrmeNxvOfwoAxbbQ7xT8ykqenFWZNLuoxn7OeOhrqbK8aQg+XketT3U8rqQse0etAHNWVncsuZgVUVftkdHxHvz3OcCpZPtHLbsj0qOGSRmAyF5oAWeKSN9ylt3qW6U+L7YBncCvvUzwvxlw2e1WIndV2sg2+tAFGW6jiYm4AbPBGODXa+A/iXp0Vm/hDx3Ctz4QvR5EVxKc/YyeiueojzjDdUOO3IwYotLkXF6fm74rE1GPT0kZbaPeh42kZzQB03i74f6l4F19Ytgv9Eujmw1JucjqIpP9sDoejDnrkVVn0+eZcs6D1Cjiux+FXi4Qaa3hXxhCLrwrcL5cEspJNn6KT18vPRuqH2xtt+MvDD+C5sXEjXOlznFrdnv6I56Bvfo3XrkUAeX3sVtaxnzQHb0rmbm4t/OYJFzW34hufPmZYo8An71YyWCLl2b5zQBZsGE23amG+ldHa2jGAtLNtHpWb4ceKCUeama2r25jmlC28RPtQBj3UsEbeVHDubu+Kqz3cFmQyqrP3zWw+m38/EcA2nvWJrmj3EOV8pmYjnHrQA2PU7zUJAkGcHgKorpbXw/cx2RmnKK2M5Zq4G2uL3TWO1GXB49a0Tca1qgBkuHWM/w5xQBZvvs8c7K+WboSO5qKzFvGWJQKW71IlgY8Cd+3JNRXctpAgVGDHPrQBdf7IkWXPPtWLcrbzufKGBnvxUcgaVsxnimvamMqXfJPOBQA54dseNxIqOG5t7cndFuPvTZ8op82TC9hVVW80dOPU0AX7jViy/KAg6cCsieR5WLDgevrSXJVSAGGajBZ1AIOBQAQy73Chzmt7TLZDyMk+9ZtlaoX3bTmtizt7mWUJCCE7mgDUMkUUWzq/oK53Um2Sl2T8M10FzH9kgwBl8ck1y11K0rn5S1ADHuPNG2JRVadWUYbrUiuttHuUfP6VXadm+eRevQelAFcqwPSkK5XLcVYWUMfu00xB5OuFoAhUE9KftHcnP0qVY8nCgnHpU/2J1XcVbn2oAz5pJGQJGML61aitCY1JYc054imARlvSrsVuTGpKnNAFK4wVBVBu9KgSOQnONo9KfcyuZN21lPpiqb3jLy+6gDQJdRhhmmBk3fcUmqR1BCudxPtjmo2vgm1gh2mgDSijaSXOCuPTpWpDbTSptRgMjqapaZdpPjHyj2rYj2K2Ynww6n0oAtWGjzxqJDMDj1U1rLdywxlWKsf9kYrGF1es22ORnSr0N0kCbZly3XnrQAsD3VzKdpIOeBWrEzoQk9umR/Ear215CxzEMN2OKbdO03E0hUeooA0hZT3PNuoVDxlWxUL2M9swMl1jHbrTLZIlAKXEp/4FgUk8U0rAoSwHcHNAFtF85MbyffbTE0mSaTdHKgPoQaktUlRPl38dyatW0Ms7EJIynvzQBVbT54mAlkU/QHNPeK4HysG8v1q9PC9uAZZGbPSooJLsyYZQYaAMiSAs37oNJj1NadhpTzBXdVjx3NOuoIyzGNtknfBxWbJc3MaNErOV7nNAHRy3cVlFswGHQgd66HwZ8RtOFu3hLxpb/aPC96PJjml5+yk9FY9QmejfwHHbp53p8r/MJjlj0zSTRN5pd8FT2xkYoA2PiP4GvPAOqoly81/oV02LG/69eRFKR/HjoejD3yK5O4W3dd0GWf0PavVvAfj/T7bTm8KeOkS58LXS+Sk0/P2TPRWPXy84w3VD7cinr3wh8RWnjG20bRITeaVfZkh1ZxmOCIYyJiP4wCMY+/2x82ADzO0nuYySsQcelX4NUvE/5YrGe7Edq3vid4SuPh54nisFlkuNNuohLZ3MuNzkf6xGxxuB547H2Nct5rTHdI+EHUCgDptK1O7kOEuQU/iJXpW/FNG8bAL9pkPcVxUV9C0Qit8oenB61q2jpa2+XncSYzgHFAGZ4nsnjdpGhZM9h1rk0vbgMUtopWYeoruJrp7ofPNuHvyabG8FmpYxqW9QKAOOFrr+ofIse0H1p6eG7iDLXkmGPYGumbV7qVttnbsOcZAqOfT76Y+ZOCgPqaAOUu1a3ytt19aos15/dLN6mu5g02AEBwHatSHwwtxEXOEFAHl5WYgeZ94nnPahNPu7ptkSyFT3Ar0tfDltCS8q76s20kUJ8uKFY1H8RFAHDaV4QaZg19IY1HpWld6Vp1qnlwq0rjviuxF1aFCo2n15qlcXOn28bFWQSHtQBylhpk08oCRmMehFdpp2gSwWvmSRqpHeuejvpRP5qNkegFXZvEOozrt3hY8YoAzvE+/d5UQ65Fc1JbvEn8Kt3NbzvJLIzSfMapXUGUJl4PtQBz72244kOX9RUE0ZUEYKgdSe9XiXD4gXPuabLp80zh5nJz0A7UAZHLMRENxqVLS4dwuRzWvZ6eqSHdhR9avFIYiSMH6UALplhBaIHuWGTzj1qbUL2ER4jQe3FYl7eMH2ryKsafavfOASQtAEVvEJ7jIGX9a6qDSpGhU+Uh471qaLoEFvGpYLn1PWtg20IPE+B6ZoA4mz1DTBKqXlqCCeuK7Gx8PeFtWiG6JQSMcV5rL5MZALlj7VtaY8Me0xXTxk9jQB0GqfCfSJVLWTsvpg1y+o/Ca4iBaG7XaOzV0Ca1e2wIjvQV9Caz77xLdHImm3Z9DQBxEvhXUtOmKiZMZzx3q1bW1zDgyjdzzV641Tz5MfOartO45Ut7ZoAvpJIIxgFFps91bkAEMz+pqC1d5n/eSEA1qQ2UW4PkP7GgBunq0g/dIc1qNpk8qZaZFHpmojHMV2w/ugePl4oTTZjy0zOT6mgCCW1aJwrNuX2NdFpaxxQBuAO+TXP3liITl5CfxqewBkGEBYduaAN9Lg3MhjjwB61MwexYCOTk9sVVs5VtTgWmT6+tT3l27J+7hEbdqAKeqXzOpErMSOwHWqsF3eBSsWdvuKmRJ5XDykkjvU8kUwAIIHvQBHaQ3XmCa4iLA9qtB5pZCFtCFHtU1nOVVfMuhx/CT0qzNMHjPl3AB9qAMx7UE5likT6YpI7GN5Mhm2j+8asGaZshwpHqaqOpLNgEsewPFAD20CPVb+3svtlrZxzv5bXFy37uIHu38sdzgV9ceB/D9r4V8KaZoun3E9za2cISOWeQyM465z6c8AcAYA4FfIMWjzSgs3yqeoJzxW54X8f+IvAlxHBpT/2hpgPz6fcsdgH/AEzbqh9uR7UAfRXxb8Fx+OfB1zp67E1GE/aLGZh/q5l6Z9jyp9jXyHBp904Md1EbeWNzHNE3BjdThlP0IIr688BfEnQPGarDZzm11QLuk0+5IWZfUjs491z74ryb9ofwiNJ1mPxRZh0sb91hvVT7sc/RJPo4+U/7QX+9QB5StrBFIoiUbxRfSMxVTH06kd6m0/yI5yXDSZ/vVp3EBkgJjiHtgdKAMaIgkIibT6mtSzaytRvvdrj0rDvWlg42SDHXPSqMt5byRHerbxQB27+LNDsIyYo034yBiubu/FT6tMTGBHEORXBaiY3uCwbPPTNEN35a9MAdMd6APT9NjScpsfDmuv0/SZ7gBVn4rx7SdXlR1d2K47CvaPhqZNSkTc7AGgC4/ge7ni+R2Ncpr3hHUbQEbmJPYV9GmNLCzG1lyRgk1xmv30BWTIDPjg0AfO9zp95bttwV+tZ8ulXDzBiCTXceJg7TFz8o5NZOlTObnBR5h2HpQBiy77SIKI28z0FNj+0ycyRlR713iwo2XktFz2Jqnd2YkJ4wuOlAHHveQWqky8t2ArEuruW+lIhjkKewruhp9kzEPDGfUkUsz2dpHss4k3+woA4y1tJ4VzJEd/pipZfNSMsy7fXNW9Rv7qF97AZ9Kxbm7luWzNIcHooPFAFG7uW3Eo2TTPtDqeMlj2qdo1XkKoqDIUgxruPrQBoWOnNcOHYAZ9a21kSxXZEqlvUVlQSuIgdxz2FJJdeUd2zc59aAOgtr+4bB3EsexrUSSZlBKDmubsLlyd0gUNWj9omPIk49jQBwwJH7zkexqzDebMbic+4qk9xvTHANRLPkgSDj2oA3knt5x80hzVgW0GwsmCfc1zAKBsoTUy3Ew4VyM0AX5yQxGAp7YpsaFh879arIZG5ZsinicZ2nr0oA047ZWXETcirMDSxNhM596q6e2w5PIrZQLJhhHIT6qRigBI71zxI4GPSpVvFX7kwz71FPmNTlEwfVTmqBUSSDCHGeeKALzTi5l2NISPUVp2ls8a7oN5qlDHblQNpV/XFWYPNhfctzhB1FAGmguFG4qx9qSeeSX93IjoB/ERSpqMEKhmuCzemKSXWxNHtIkK+gWgCN3njXbbEP9antbe5uVJkJ47CqQuoxllt5vqTV2212e3jIFqAnrnmgBHtyjFDbsWH8Rpscawt+8YfQGo5NaE74BKbvWlNyLRd+wSH160AXkka5ARYW2juK0LOExYMlrlB3J5Nc/Fq93cyhYyIU9cVs2txGgXzrmSVu+OlAGhc3MLDEcLgdDWPdJI5KpFgH+KtpdVgRNqqFz3IrD1bfNlreRjn8BQBTl06D5JDIBcxNvSRGKujdirDkH3FdxoXxRvZtMuPDfj20k1vQruMwPdwgfaolIxlh0kx13DDA9jXll5N5JIdyH74NQw3HzApJLuoA7Sz0OS0neL7TFexROViuo+k6fwvjsSMZHY5FdTZ2UuwYjXHqax/CduZYFluJ2PfBrf1KQhALby1J7k9aAM3UrKKSQLMin1xWDq/huzuIWEJCeuK6SCR04nCOT6Cg273LMIk2Z70AeO6t4Z8iUsuSB69TVO30iZlO2FiPcV6rf+Gme43SzH6dqgkspoR5ccPmLnHAoA4zQfDplvEa4+VfRjXvng1bXSLNWCqCAOa8xstMuVvPMlj+Qdia6C716Oxt/JVCzYxigDvtW8WwSApuLH0HauXvtchkyWChcVxCS6jqEhMJSEE8n2ou7N7WMtPcCRvQUAP8QaxbTgiMZPTpVHSbiZPuQ4z1NQWk9srkJGCc87qddaqsBPl4J9B0FAGxPqfljaEZ2HUVDZ3DXW4ZYD3rnptZmkUBkUE/3etT6Ut7cTqquFjJ5NAHQxaahVjv3k9hWHrMQ0/LuAn1ruENtp2nkeYnmY+YmvMPFF1Hc3DP5xlGfu9qAMLUbs3Um4mq8cSk5JJJ6Y7UvkNI2dhAoFnIWJ3kCgB8lqrL8z4HtVSQpGQkeM1JcAQj75PFUlwH3sPnz0oA1bUhE3Mcn0FaVrboxMjgVnWhXGTxV83KhNqkUAMdF84FmCp9atjbjhjiqUcDXMgLZCVorbkKAqkgUAcO9lOOq4qBoXjYZyBjkV38ujoGI3n8ayrrRmBPzq1AHKgkZqRUJXO45q9dWPlkjawI9qq7CnXgUARBpE6McfWrMMu77yc+uOabtjz87FTT45Y1YBSPxoA2dMMTEbiw+tbbN9nXdHg1zccLyLujIB+tWFhu1I3yBh6UAbttftKcSLxVlFaY5iGF74qhYpIkRaQoijklq0LS+t4QdkqFu9ADpnhhG1QzN71WSIzuOGVfbir6alb/APPJXPtUg1IZxHa/QYoAoNH5Iyo3H/aFOt3lkb5sD6dKsXM0ky82+z3yKoRhRJ802CP4RQBZmaSFv9YuPemzatC0ez5dw68Vm6k284Abb6msd7nYxVVX60AbRuYGlDNj6CtG21Kyb92d2a5AXDbvkxkflW3oMqyuRJEC3tQBvR/6QwFtgKfWtjTtOmiO+VkZfTNVrNAjoAgGa6Ww00TPukZVU9s0AYWqOmQDFtA/iFZN3dMsbbjtj9M12HiGyijtyLeMswHavJ9fllVmWQyDnoKAEnmWaYhGyM9K19Dj3SqHU9a5awlPnLhcnv616HoNpFJFvyd9AHW21p5Vqr5xxwBWVJHM93n5wuepqRftKyJtcsB2ret1jni23PyHvQBWh2xwjDmR/rUhuZFXcCVPpUsos4BiGRT7jk1Hbo0rkunyjuaAMydb+6lDJI230zWhBJJGoSQop9ammcpGwt1BaskfaZZfniLEc4FAGq0cbxMQzMx9K4jxGk0JZlD9Tgk121tLchNoiVR7iuf8QQOcl95z6DigDhvt11CuXmdfTBqOXU7iUBVZs+uas3iIhO8DHbNSafCsrhmCKo9aAM9YLrYWmZ9x5ABprRXjR8Kce9dVGI5HxEu/HfHFW0hY4yoYnsvagDmLPTpyFIQg+pq8EuLRcx7i1ddbaZf3SDy7Vto7gUXeg36RbmjVZOynrQB59fz3s/M7t9CaqxpEGAkIzXTajoeorlprdwD6VkDRZnfOwxgf36AKk4URHa4qmsbNzuJx2FatxaovyDDH1FQyL5Ue2NCzH0HSgDCuYiJM4yfSmx2ruAQoJrTa2bO+UhT6Go1mVZNqNn3oApGKSMgNnNWbSJ2JyABRcStuHQ03zXK4BAoA0FnEKhVYEntTvtMp/jYewNZsCRlgzSEt6VqpDEVBy34UAdDd3sUhymyi0hF0GCsgbOK4trrZgnJ+lX9O1dA4+Vx9KANnUNLlhY5RZAe9ZMmlrKpygDVrtrLY/doW+tUrjUXlByVQ/TFAHO3Vi8TndHkdjVcW8ePmjArRmn+Yl5t1QPdw/d4yeKAG26KSFXeK2bGBQu6RyB2zWXA67/lA/OrzKXQblJX0DUAaotkl/wBZMAnp61Vu47KD+M/gKhUxKgHmOv8AsnnNOItyuXVm/GgBtrLbI+V3Eepq5Jdo4wgOe1UPNhAPlphfQ9adDMO0JY9uaALkSNK372QhPTNWpEtbeLKbR9etVFZ5AP3AUeuaSWOIRkyAk49c0AY2sXBYFY5OvpXOyO+7kkmtLUZ0WYhY2wapLC0h3AgCgBkLylhtrqNAkeJgWj+prIs4NpyR+OK1LW8mjbCICtAHe6RNbTlDI5BFdMTEYgIWB9DnrXnGnTK0imT5Sa6ezaNXGwuW+vFAF++mv44z5cO4Y61xOuCOVSblAr16C1xMtuSq5GOtcJrzLPOTIhyD2oA5mGCRrnFuFVPWvRfDEMcUAUkvJ7VzFjp/mvmFNpPcmuy0OzW12madF+hoAt3D3kUgLIoi9e9D3iSp5fl8nvmtK4kt5l2oGkOO1ZlzEkK5lXaD0HcUAWtPsyrr5cakE9zXRPgQbZNo47Vy1jHNKw+zyMorcFrLGgadi340AU5bRZH3HIUHjaetX4JfLQJFCB23HvWbdX8dvuAIJ7DNV7O6u5XDbMR54waAOrtFuWX5IEZfpWV4gglC5bA9sdK1LG+kt4v37hVrL1bVxdBlRPlH/LQ9KAOKu7ESuTIF2jnkVWFpaRcuwI9qdrjSHPlyl/cHiuWeeaOYDBIPvQB2dot1eSCGwhWNOm7Feh+FPC9vDskvZFd+uK8z8O60UUIylTmvUvDk4uyuHGCOeaAO0a2Dw+VbKiR4xkCs+exsrCMvMQ7jncxrSFxBp9qS7D86888V+IftUpjjX5PWgDO8Ua7H5rxwbQBnJ9a821K+muXaMEgeq1p6oVkl5JYk8YNUWhMY3YwfTNAFC3hEI3zP+BqC91dUUrbxKD3JqDU51iBVmBrn7i9V2CgcigCS7uCxLzSkknoKgimDH5VIX1qHBd9zdPepQQ2EwfwoAnTa7csTj0pcKX2gmp4kURqpCgeo4p0jQ265QBm9fSgCEQskm4g1aE0uBhTj61Bab7iUNO+EHpW4l3bIoURZx320AceLn5gBu/GtWxvY4iA4XJ5rE3L+NIXAHPXtQB1o1iIZ2AfjWZe3sk7HhAD6ViiQKM05ZN3RsGgC1tbaeOvrT1gwM/IfSqLscfNIcUyJiXAVmPNAG1aBkcZWM5966Oz043yjDIPda5e2iYgbicDvW5o1ykM2VmYEds0Aa03hoRR7zK+QM4NU/sYU7FlXPvWncTyXMYxI2PSqAfyWO23dz3NAEL6Y0mD5ik+oqtNbrbcsznHpV5dRSIkNA4NWomhu8cAZ9aAMK3nllYpDG5/3jUk9tqQjJIRV9zXQGwgRNyyBT7Vj6ok5UhJHK+tAHK6jcyRPtcKWqtCF8wSMzA+gq1eWTq+5ny3oaigtpXPAGKALy3O6MJGMe9SWgug2V2n0pLe2kzhl6VoWybXAVDu9+lAF2wWVseYV3HvWzZ2VzK4LXJVewWqNnAwwXRQPrW3akAYx8o64oA0I7a4ijwbssmOd1Ztx9jSXMxyR1NWZLiCRCkQc1z+qW8vzMowvvQBsNc29x8lnCxxxkGtbTtOmlVTsAPua4nRhcLODG20Hqa9B02e4jiGHBGM5oAvpFNaqdzIMegqmFa5lLMC4z3pl3qrqQvkNKT6VYtrmfYD9lZAR6UAaEerQWUODbEsOMAVDcX9zfIGWNkjPaoPMckk2+fcimNNdSr5awlQPSgCpdIEk+ZUJ9T1q9pzrGRsO4nsO1WrHSmkG+dT681JcpHCuEQAjuKAJJ97J0zn1NZjlGys3CjjC9Kjc3NyxCMQKbc2NwIOetAGDr1kJo2FoGXPoelcRcWVzbsQ8hdvau6nguvLbJYY9O9cjqdve+czgFR6mgBumLLC3mSPtHoa9J8L+Ibe1hAc7mHoa8ncTE7XkqaCaeFgIs5oA9n1jxPE8RZ2AU/wk81w+p6+9ypEQCDpzXJXJvJ/mZy3+zmm2sDbx5zsT6UAb1vctEpdjuY96zNRvZppOXIqxIWSH7hAHQnvWLcvI+Sq80AZ+oHdnAcn1zVFcRqcrkn9KuXG6MfOaqqy5JJzQA8hXTLA4p8c2xP3S8+9VmxK+1XwK0bOyjY5YnigCFYJJTl5QuewqcWjHC847k1c3WyEKAWYdKlRWmO1FIoAls4Y4owAN4q+ofaNsSY9xVrSdFmlwxGFrqo9KgCKGIzjmgDwcEgdKC24jPWhI/m5Jx9ad5HO4fnQBFIG79KehIHWnFV/ifn0xUTDHQUAWFJBGQDU9qse8l/lJ6EVBaglhxV6RSVwAKANGKMsg2ScCrcK/MCEBb1ArO01ZVcA4K10URiVBvG3PpQBZsWnVcQlSfQ0+4nvowdyKB7VWU2itmOSQNVjKuuA5OfU0AUSWuWLM2PfFCq6ci6VQO2KkubGZv9TJjPYUyHRLrId2zj1PWgCV9RjhQblaZvYVSm1aeZjHbWbEHoDWo8MsEeGjTA7gVAkuwnapVv71AGedK1CQeZJaDHXJNTRabIFzMqRgfWtqzupJF5lkLdgKuXGmXdwmfMwpHc0Ac0IIwfkO4eoNK8N+/wAlhAGz3NbEWhvuwCxPfFdbo3h24SFSnIPYigDz+HRNcPzfZyxPYNWxpukawgK3Fq6r9a9GEn9mQ/OgZhWLqXiO6lZo4tqLQBiTWbW0eXjZW+tc/e3E4ctMw2DotaurahO/LzLmsKSJJGLSMWP6UAMj1KZm/cIFH0rqPDlx9qIFwWJz0B4rjZuH4YYHYCtLSL9bVxtfn0oA9LvIYbaISRMA+OBVWxvbqWT5iSv0qpY3H2pBJKQR9a1LfUbaEiNhgdMigDWjgmnQeVj15qpd3JseJXUn2q0JYWtiY7ggHtmsO4hRptxffk96ANC01WGdgDFMy9znApb24t5f3cEQ3d8tzVBbO5n+SFyq5xgDFXF8NSqgkdgD1znBoAdDDcFFWLy0rVtrWRVPmfOKo2MKwnBwxHvmtaAXTEHG2OgDOvYvkKiEKPXHWuE8TwqikbCSfSvUbuZIoTuGfc1534qnikRvL+ZvQUAcXDDGmdy+/NMkeFW+bAx6VVuY7pnzyorKvmEGd7kk0Abj3kWMIRmooiHm3O9YFt+8bO7rWtbxRIhZnJP1oA3Y/wB6wyw2J1yapanc2sLfJIufasW8lLkKsjAeimqwgRRuZizehoAfOyS/MFOPes26lG4LGufWrkrSsmFwBT7ZI4jvbBc9sUAVrKG4lOIocfUV0Nnotw6fvZdi1Wjubot8irGvatG0inuQN0749qAL9rotlEQxJd/etS0hgt33+RuHpU2naO5RS0h9s1vW2kBcNK4C0AUbSe5uMbYvJh/u45rUWa4VQFgBA71bDWtshO5S3vWbJqa7z1/A0AfPcg2nvSDJOcmpY8buVpJD83yjFAAPwpWXHI5pgYEHfSDk/LQA9ZH64xU9tIjMPMc80xVyRvpZYyBmLrigDpNLgMjAJkit6ezWOEGTcB6ivOrO71C3lGx+K301m+dQs7YX0oA3be3t5G4nOO4NWJxbQpiOT5qzdOh0+5UvPMd3oDjNTyraQNmEFh7nNACiaQgYlwKe2pSRrsQvITxxTlvVKjEY/KpvNSReZAjewoAqf8TCf5tpRPenRwK2PPnZB7Va+Xb/AK92ohjmZ/3artPUtQBq6a1nbIPLJkPqa14/37I3lyKvr2rMtYo7cbsq7d1FXbdprwhZAiRg8DNAHWaXY2KJvmuAO+DS33iCztVMVtcKzdgKzFkhgh2sqkeuayr37BLyy4I9KAF1DV7u5Zgi/Ke5rHlhnwZHbr6Uly1hACYhKX+prMN5vkIZZD6daAEuIHlfJOR6U1laGM7k4p32ks20QkZ7025tFZd7bs+maAMu5m3g7VCiqKonmAtNg1cljhDsJFJ54ANULmBA3yLtWgDdt7yS1VQlyWHpmtSz13b/AK1Q6iuXtMBMdamUupJDcelAHa23iK3kk24KDFdHp95YXJQNIMn3rykzyLglMipbXXfskwZ4W4oA+hbG0tXt1aOYjA4xVO+sruZtsZd4x6mvNdH8f+UAojIX3rs7DxvZzwqLh9q9+aANKHyNO5uCob/ap8mvQMMQvuXpxWddeJdDkTbBAZG9TzWcuvWquIoIQCT6UAad/NNfHbH8qevrVSHw2kuWZ8sa0dB0KfWpxJJJIsec4XivQofC9rYWoL7ycdTQB4zrHh2OFWIxXkviUwRXTR4yQTmveviLqUFlaSRxsI2wQPWvnXVPMubt2CHk/ePegBbcIQu04FWnYE7QDiqKxGNPlf56sQh5fvdaAHYWPOR8x6Zpjs3UjmnvC3RQcmnQWj5zLnFABb2xbDzPgelaEUKN0AAHc0RiJEwOvvVeecghQfwFAFh0QH5SW+laulhhIGPEYrLssEZlWtqyktWbbnAFAHRQansXCjcB0PpUdzeXtweMqnbBqjJdW6psRwoHWqM2sC34jJY0AbUcTkZnlNO3xjis3TL2S+cebiusijtvLXO3NAHz3g5zmlz+NG7tQykcr0oAY67iPalTijDNT40IPPNAEi4I4NSxq4+6M0gQH2pfK6HzCPpQBoWkEhwxtyBWhmHGJE59lqnp15KmI45N3+/WjNb3jqH82JR6AUAVfIG7MYKg+1aFrpc86jZIB9aptK5+Qygt7VPBcOgwSxx6UAag0aaJOZFZvUVRneW3yCiv75xTE1OeOT5NxU8YNSSMJD5lzlR7UAWLVUnUYcox96vQaXIzZad9vtVSymQECJsD1Kit2CZUG4zsx9lFABa2sUBHLse+at3LI21beGRpPYU63Fzc/wCpViPUqK17Vbq3T/VDf64oAyLTSL+Zw82+NB2NaMVpAkgWQAn60t8NWuI8tOscfp3rOWe0gBS6nYv3YUAdIo0aKL/SFTOPSsLWNR0gArawAY6HHWs641Sz2HyLWaU/3qzZEF2SdjR57elACPKJ5Q0a7V9DTLwqY9quN31p62AiG4zH6E8VWuISVOXQD1oAyZreTzSV655PrVa5VhwQc1cmVt22NnY+o6UDTLiQbjv+pNAEVlbkKWc4FOdlydnFLsuYTsIyKWOznmY7EK+5oArvdyK2w5Yey1G/myj5Yj9cVuW+kAgGe4B9h1q0NPgK7RMwoA5aFLsyiNY+TwOK6iy8N3zwiWc7U64pq2htnMkcwZgeM1Mb+/mKr57tk42KDQA8LMkwtrdGftla9Q8AeDp7x4pLqNRg555rG8I+GNcvZEljszEh/javdvCui3VpbKJSqkAZNAGzpmmWmk2i7I03Aelc14x1uVLWUDagAqz4l1qHT4yrXamQfwg15F4r1G61YuvmlYiOoNAHn/jDU/tV83m/vRzwDmuVMayc+XsGeMiunvbHyiWDIp6e5rEntpS3yZPuen4UAZy6eJJMhc+9OeyKD5EIPpWzbQtBF+84NZupXxU7IyC/agCmxCY38EUj3KPgCqUgndmac9elSRbYo9wXJoAmdd3PT26063tmL525HqagE7u2Ik49TTzcFcLuLH0HagC/MsSLhmIPoKpJK6t+7RvrR52PvEfjSi7bPADD2FAEsYcnMjEk9qV4Znb92APqKFmfHyJj1zTonnZvvgUAW7BLi2P3h+dagurggH7QB7ViyNJwGJpywkgHc1AHBhR2FOxinSBR0NRF8dqAFbmkVRweaFbrxT8gigCWNjwO1OkZcVWLHt0oDDuaAJrK5aKQkDbzW/Z6n5mBI52VzBJTJVck9s1Zt5H3DIGKAPQLO0tbxQYzk1ZjsYopNu2uU0zUmtSCh49K6az1qCRR5vyse9AE15p3GUTB9cVRFsEYCb5h3Fb0FzHc8LMSnptqeTS4pVOGA/GgCjYS6XFgPbDd61swXVkwHkxDmqcGn2MJxM+72FaenNp1rJ+6tZpcc5C8UAWbWO5Zf9H8wA+gqK80jWrg7lifaO5NdTpetMigR6e6qPVa7DSdU0x9v20yIT1G2gDxS6s7+3Ba5SQgdhk1mfbHdtqWhx03MK+oo4/D96m2CFXJ7sKz7rwFpl3IXiWIMegFAHzsFu/KPlxKAazZrS5dmaUhfpX0XN8NHwfLVCPrXO6j8NrvzdqWzH3HSgDwB4J/tH3mYDtWgIpNn3K9h/4VjfZO2HnsFGarTfDTVfMwIwo96API5LWZvu8H0oS21DG1c17BD8ONQQ/MqsfatG3+G99MPmjZR7jAoA8btNJvHO581Zl0i6YfKvT1r3ax+FkwUGWVFX/erdtfhtYRoPtF0DjqAKAPnG00S+nIXyx+Fb9h4BvrsjO7n1FfR+neGdD09BshR3H8TVYuLnSrUYO1QOwWgDxLTPhhNtVTGrE12ej/AA8XTlWWWOPcPUdK6a98Y6fYKTCgJ7E8Vwmu/EOW5LBGAXPAVqAOxlv7XSofnm6fwiuR1/xrcXGYbGR1TpmuGvdbub2b95METPfmoJLobCqSDd6+tAFq6aSWZpJ52cnn5jVK6kxHnNVXZ1G+acFewFYmp6qTlYRlR3zQBV1i6lEhPmBI6wJNWRDiMNI2evpVi+uFlBeUAD0JrIFwoc7QFX6UAWJ7u7uOp+X0qqsUinO4Yoe7Zm2wIT71A/nlSD8tAEjhNwZ2yaa0isflqMRbQCzZJqSODcck7aAGgy9ufpUsMLysC/y4pZJViX5cE+xqv50xGQD9OlAFyaOKLqwNOtyjEbBgVSSIv80hP0qRJlR8ZxQBpSoETKnc5psJKfMw+amJPgDj8aRpiTkdaAHb2Mo4q6JGwOKow+c7g7cVfELkD58UAcEyHvTCuB0qYqT3pNpzk4OKAIRn0pxPtUhZe+fwFNxk4FADSM09Y1P1pwjz1607ymHQUAQ7TnBp6rngHFDsw4IxUYfbzuoAsqm0cMc1aUS4B82qkTCRcZ/Gr9vEGIUstAFuxvDbuC0i/iTXTWOvAx7TM304rnBpUcg3M+fpTvsltCOWoA6+2vpJJNyyHHuBXQ6bq6RBRM34jFeb2rhTiN8CnyuxYgSnP+9QB7Pb6vAyjyp/mPQcVqaVJLcShjImP9oV4VbXEkbD982f96us0XXZYdgaUtj3oA96sHmVAI5Yx/uirD6jNbN8zk4715xpviGRkUh8Vcl1iSZwDIGHpmgDuovFkwfapY4q+njGQjazonsa87j1GIJ85BPoDULana7jugZmNAHpUWtlss0yJn/apj6kWlz5xYexrzeS6lA3RW4Uf7RqWPVL0qAqIpHvQB6MuoMDlZHI9OKmOqRqv76R19ea81F/qZB+cKPYVE93eOcOxY+4wKAPS38T6fBkAucdSTWbdeNrZjtjcr9BXCjPWV0J9M00mRB8kcar6k9aAOrk8UvPxFHK5/Ss3VbvVrmLICwoe5rMi1n7Mu3bGWHoKqXmtzXOQA5J6DpQBm3OnXlxMfOvWwT+FA0e0giZprpc/Xmqd414+VWVIye3cVntp/zbrm8LOewoAmlNnFKdmZqp3moNGpJjQL2HoKne08uMsjoB655rB1JGMuA5cUAMlvHuX4wid+etVZkyjCNuvNRGPafm/Sobpyq/LQBn3kUaf60mU/yrOkyTgHCjoK0G3yN8+MU1lCg4AzQBUS5kRdoUD3phkZju3UsyyMxJAxUKdfnIAoAnCM5BFWEgwPnY0yOSJFABLH37VJKxZPkO2gCFlgjbAHNDFiQCRjtURCoc5zTPtIBK7d39KAJlcbsGnLCu/LDmoBIeCOKeZGIwGoAtySqi4wPaoY7pVblc1UZG3Zb8KnhiB5oAuvekKQOPpVBp5if9Y1SNASQDVlLQFRxQBzrxkGlEKsOeoqXypm+9ikMTqufSgBvlumcBcYpoRfXFRtIc8tzScnmgCdfk9DT9wYdQCKqnJ5zSjAHXmgB0hVjtYjNQvAq9OTTsrnJXJpd7scJGT+FADYnEXYDFXIrxQM7wD9KptHKSAYyamjsbiTkRMB9KALZ1STtjb7UfbPMGW61ENFvnx5cfH0q5b+GNWlwBHweKAIYp8PncfpVsXfYDkd8VZh8Fajnc8b/QVcj8H3PH7qQMaAMuO/HO+PIHtU0ereWR5aMK6Oz+H9/LgqrDPrW1afDm8ABfb+VAHI2muXLHAZ1X1ArZtNTuMfcmlH5V0tt4HNq+ZmXitWDQMEBW+X0AoA4/+0ruX5LaxmVzxuLE1d0631jO+ZjzyATzXo2m6NIyhUgBPqRWuuhGFPMnCZ+tAHDWMd8VH2lWYem41pLEzkBY9nvuNal7PDBkYyR6VmG+jUnHBoAuxQxRDM0zE+gNOaPz8iPdt9zWYurJBJlkU/Wrv9twyR4+UD/ZoArtp8Sy72d93pUyCBcgqCR03MaoTXk8z4jHy0sTsCC4DkdvSgDWVd6Hy4Eye4Gar3FnIyYP8sVXfUJV/wCWwRB2AqrJrkzHZEC59SKAH/2efMBKgY7saivEt/utJGT7UxoL7URh5Sin07U6PwxBGN0s53dyWoAxNQjs7dCVdmb0zXMzXFxPIVhQhPXFd9cWGmRD945bFZWqX+mWcWY9vHYdTQByBBiYDy3kbuxFOe3kuB8sYH1qyb6a+k/cKI4z3Iq/FaLHHmZ859KAMH+zokUtPLtI7LzVO6Fui/u9zE963b1kXIiiyPU1lNGjMTjB+lAGUsYYdDULQRK2dn61o3J8kcEVnsJJcbelACEJnG0AnpT2jZ1wBgU+3s2Xc0pHtTZ2fohoAgFtu+Zzj2qQQJjIAHrVSQyBuTSCVhwG470AWJYx0Q5qHAzjOGpMt2NPiC4I2kv60AMxk/MTgdSKniViPlzt9TxRvMa52DPpTSJ5RlwEXtQBZEsMWNzlqtJewlRgVjNHhsHnFP2v2U0AU1jlQ8vmnsHxzyKbGSX5q8qjy84oAypIVYjGRUkdmh5Mzf8AfNS3CjnAqKNQE7/nQA5rSLd99j+GKnsolLhTGGGfSoIciUjJxWvpsamUEjnNAHRaLpemSgG5hcD2Suoh0Xw+E/dwSE+pXFR+Ho1ES/KK6RQAOAPyoAwhoulxMGS2z+FaMenadLGFW3Ab6Vq26q4+YA4qKUBXO3igCG00K3L8IBWh/ZsNuOVQqOvNQxyv5WdxznFOgHmPl8n6mgCxEbVOkWf+BVcjuIeqIikeoz+tURGgJ4qjqA2t8vFAGzJfXkmVt/KA9duKakOoyOPNuNqH0NU7WFFjVhnJ96uxyMpG1jQBrWGiWbEPeXmW7qWrcit9IVNsYLY9Grm1dmiOcdKXTBznvmgDav7mGzUmCKUj2rk9S1ySQsojdR71vX7HZ1PSuYv3bJHagDNlaWU7nl2rULy2yDDKWPrV9IkcDcM1UuI1D4CjFAEEZtZWO8Ej6Vp29zpUEe0Qgt9Kyb6VoYP3eFwPSsiK7mkch3yME9KAOzF5BJ9yNEX1NSfa9OiUtcXlug75IrzXUrqcow8xgPY1kQ20dyy+eGfPXLGgD0jUPEvh6Isouo5G/wBmsKfxZpyhjBlvpUFh4f0zyg32VN3rWjFo2no422yCgDCk8WajMStijID3xVR7zWp2IaeRj1x6V3DWFtDFmOFF49KiMMYXIQZoA4k2uqT8zXMq/jTk07yRvl3Sv712UUEbt8yg03UI0RQFUCgDlka4UZRERfQ05UupRuaVVj9hVif/AFuO3pUdzIyRAKcCgDLu5khO0ys59Kr75pV+RGx6mtfyIzhigJxms2+nkRiqNge1AEC6YT88s3XtUdxaqhI8wKB6Uwu3l53HNOSNXZiwz+NAEFvbPPJiLe+P1q+NBvniO2MIPU10Xh2NFgQqoHPpU+u3EqoQrED2oA4yXRTEP38may7mOCI4TGRV3Vp5fNxvOKx/vuS3PNAEnmJjPFWreQniNMCqaRJu+7UzuyD5TigC1JJtwWHzdqrFndss4Apbb99v8z5sHAq6IIygyg6UAU0kyQoFW1HHWkCKGyBSHrQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view of upper abdomen at 32 weeks gestational age shows a well-defined echogenic mass (arrow) in the left upper quadrant adjacent to the spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16689=[""].join("\n");
var outline_f16_19_16689=null;
var title_f16_19_16690="West Nile virus infection";
var content_f16_19_16690=[" <h1 id=\"patTopicTitle\">",
"  Patient information: West Nile virus infection (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/19/16690/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/19/16690/contributors\" id=\"au6239\">",
"       Lyle R Petersen, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/19/16690/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/19/16690/contributors\" id=\"se636\">",
"       Martin S Hirsch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/19/16690/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/19/16690/contributors\" id=\"de1811\">",
"       Elinor L Baron, MD, DTMH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?16/19/16690?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     West Nile (WN) virus is an infection that primarily affects birds. Humans and other animals can also become infected, usually after being bitten by a mosquito that previously bit an infected bird.",
"    </p>",
"    <p>",
"     WN virus was first discovered in Uganda in 1937, but it became a household term in the United States in 1999 when the first cases were reported in New York City [",
"     <a class=\"abstract\" href=\"UTD.htm?16/19/16690/abstract/1\">",
"      1",
"     </a>",
"     ]. During 2011, WN virus activity was detected in 47 states and the District of Columbia [",
"     <a class=\"abstract\" href=\"UTD.htm?16/19/16690/abstract/2\">",
"      2",
"     </a>",
"     ]. Outbreaks have also been reported in a number of other regions, including Canada, Europe, Israel, and Russia. Although there is evidence that the virus has spread throughout Mexico, the Caribbean, and Central America, few human cases have been reported from these areas.",
"    </p>",
"    <p>",
"     WN virus is a seasonal epidemic in the United States, lasting from summer through fall, with a peak in activity around late August or early September. The duration is longer in milder climates, where mosquitoes can emerge earlier in the year and survive longer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WEST NILE VIRUS RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Mosquito bites increase the risk of contracting West Nile (WN) virus, particularly during the summer in an area where WN virus activity has been reported. However, the chances of contracting WN virus after a mosquito bite vary, depending upon the time of year and geographic location. About 1 in 4 people who become infected will become ill. However, only about 1 in 230 (less than 1 percent) who become infected develops severe symptoms due to involvement of the brain. (See",
"     <a class=\"local\" href=\"#H9\">",
"      'Severe disease'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Simple measures to avoid being bitten can reduce the risk of acquiring WN virus. (See",
"     <a class=\"local\" href=\"#H12\">",
"      'West Nile virus prevention'",
"     </a>",
"     below.) People over the age of 50 are encouraged to take extra precautions because they are at higher risk of developing severe symptoms of WN virus if they become infected.",
"    </p>",
"    <p>",
"     WN virus can also be acquired from a blood transfusion or organ transplant. However, the risk from blood transfusion is very low because testing for WN virus is routinely done. (See",
"     <a class=\"local\" href=\"#H6\">",
"      'Blood transfusion and organ transplant recipients'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      WEST NILE VIRUS TRANSMISSION",
"     </span>",
"    </p>",
"    <p>",
"     Nearly all cases of West Nile (WN) virus are contracted through the bite of a mosquito carrying the infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Bird-mosquito-human cycle",
"     </span>",
"     &nbsp;&mdash;&nbsp;WN virus is spread when a mosquito bites an infected bird and then bites a human or other animal. When a bird is infected, the virus can circulate in its blood for several days; a mosquito that feeds on it during this period may become a carrier of the virus. If the mosquito later bites a person, the virus can be injected from the insect's salivary glands into the person's blood.",
"    </p>",
"    <p>",
"     Because birds are the primary hosts of the disease, contact with birds and other animals that are dead or ill should be avoided, and the local health department should be contacted for instructions.",
"    </p>",
"    <p>",
"     WN virus is",
"     <strong>",
"      not",
"     </strong>",
"     spread through touching, kissing, or sharing utensils with a person with the infection, or through contact with a healthcare provider who has treated patients with the virus.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Pregnant and nursing women",
"     </span>",
"     &nbsp;&mdash;&nbsp;A nationwide study has indicated that fetal abnormalities are uncommon following maternal infection [",
"     <a class=\"abstract\" href=\"UTD.htm?16/19/16690/abstract/3\">",
"      3",
"     </a>",
"     ]. Pregnant women who believe they have been infected with the virus should contact their doctor for further evaluation and advice. Testing for WN virus is not recommended for pregnant women who have no symptoms of infection. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/52/43843?source=see_link\">",
"      \"Patient information: Avoiding infections in pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     It is believed that WN virus may be passed from an infected mother to her baby through breast milk. This is based on only one case, in which a baby tested positive for the virus but did not develop any symptoms. There are many known benefits to breastfeeding and experts continue to recommend breastfeeding for women with known or suspected WN virus infection. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Pregnant and breastfeeding women should take extra precautions to avoid mosquito bites, especially in areas where WN virus has been reported. Insect repellents containing DEET and picaridin are safe for pregnant women; breastfeeding women can use DEET. (See",
"     <a class=\"local\" href=\"#H12\">",
"      'West Nile virus prevention'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Blood transfusion and organ transplant recipients",
"     </span>",
"     &nbsp;&mdash;&nbsp;There have been a limited number of cases of people who acquired WN virus after receiving donated blood or organs. Since 2003, all blood donations are screened for WN virus to identify infected blood. It is not possible to contract the virus by donating blood. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=see_link\">",
"      \"Patient information: Blood donation and transfusion (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      WEST NILE VIRUS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Most people infected with West Nile (WN) virus never develop symptoms and will not know that they have the virus. The virus remains in the body for a few days before the immune system begins to fight the infection and eliminate it. Individuals that become ill generally exhibit symptoms within two to 15 days of acquiring the virus.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      West Nile fever",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately 25 percent of people who contract WN virus develop West Nile fever. This is a self-limited illness, usually characterized by fever, headache, tiredness, back pain, muscle aches, decreased appetite, and rash. Other symptoms can include nausea, vomiting, diarrhea, and abdominal pain.",
"    </p>",
"    <p>",
"     These symptoms typically last from a few days to several weeks. However, several studies suggest that it may take one month or longer for all symptoms to disappear [",
"     <a class=\"abstract\" href=\"UTD.htm?16/19/16690/abstract/4\">",
"      4",
"     </a>",
"     ]. Prolonged fatigue is common.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Severe disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;A small number of people infected with WN virus (less than 1 percent) develop severe neuroinvasive disease, in which the virus travels through the blood and infects the brain and spinal cord. Although people of all ages may acquire severe disease, people over age 50 are at higher risk for severe disease and should take extra precautions to avoid mosquitoes. Severe disease in children is uncommon. People with certain types of advanced cancer and those taking immunosuppressive medication after organ transplantation are at very high risk of severe disease after WN virus infection.",
"    </p>",
"    <p>",
"     Signs and symptoms of severe disease include headache and fever, as well as disorientation, convulsions, muscle weakness, coma, and paralysis. These symptoms can last for several weeks and long-lasting neurological abnormalities can develop.",
"    </p>",
"    <p>",
"     At one year, less than 40 percent of patients with severe disease achieve a full recovery; full recovery is most likely to occur in people who are less than 65 years of age [",
"     <a class=\"abstract\" href=\"UTD.htm?16/19/16690/abstract/5\">",
"      5",
"     </a>",
"     ]. Long-term neurologic abnormalities include muscle weakness, loss of concentration, confusion, and light-headedness, which continues to affect many people at 18 months. Recovery from severe disease is variable; some severely ill patients having complete or nearly complete recovery. Only about one-third of patients with paralysis will fully recover. In about 10 percent of cases, severe neuroinvasive disease results in death.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WEST NILE VIRUS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     As with any health concern, possible symptoms of West Nile (WN) virus should be discussed with and evaluated by a healthcare provider. The provider will review the person's history to determine the likelihood that he or she has contracted the virus (eg, whether the patient lives in or has visited an area with WN virus activity; recent exposure to mosquitoes).",
"    </p>",
"    <p>",
"     If a person's symptoms and history suggest that they have WN virus infection, blood is drawn for testing, particularly when severe disease is present. The most common test for WN virus detects the presence of antibodies (proteins) in the blood. Antibodies are produced in response to a foreign substance, such as a bacterium or virus. If antibodies are detected, it is a strong indication that the person has been infected with WN virus. Blood tests in patients with WN fever may be negative if blood is drawn within the first week of illness; later testing can help confirm the diagnosis.",
"    </p>",
"    <p>",
"     For most people with neuroinvasive disease from WN virus, a blood test for WN virus is positive within about one week of the first symptoms. Cerebrospinal fluid (the fluid that surrounds the brain) can also be tested if neuroinvasive disease is suspected.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WEST NILE VIRUS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     As noted above, West Nile fever generally improves on its own. Severe disease may require hospitalization for monitoring and support [",
"     <a class=\"abstract\" href=\"UTD.htm?16/19/16690/abstract/4,5\">",
"      4,5",
"     </a>",
"     ]. There is no specific treatment for West Nile virus, although research is underway to develop treatments.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WEST NILE VIRUS PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Basic preventive measures are recommended during mosquito season for people living in areas where West Nile (WN) virus is prevalent. The best way to avoid contracting the virus is to prevent mosquito bites. Mosquitoes tend to be most active at dawn and dusk, so extra vigilance is required at these times. While outdoors, insect repellents containing DEET, picardin, oil of lemon eucalyptus, and IR3535 are recommended [",
"     <a class=\"abstract\" href=\"UTD.htm?16/19/16690/abstract/6\">",
"      6",
"     </a>",
"     ]. Long pants and long sleeves will also minimize skin exposure. Applying permethrin to clothing (not skin) can further reduce the risk of insect bites. Bug zappers, sonic devices, and mosquito traps have not been shown to reduce the risk of WN virus infection.",
"    </p>",
"    <p>",
"     Community mosquito control programs that spray large areas with mosquito-killing chemicals may be used to reduce the mosquito population. Individuals can help to reduce the number of mosquitos by draining areas of standing water (eg, buckets, bird baths, gutters, wading pools, and pet dishes), where mosquitoes frequently lay eggs. Ensuring that all windows and doors have good quality screens also helps keep mosquito exposure to a minimum.",
"    </p>",
"    <p>",
"     There is currently no human vaccine for WN virus.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Birds are the primary hosts of the West Nile (WN) virus; the virus can be spread when a mosquito bites an infected bird and then bites a human or animal. The virus is not transmitted through person-to-person contact.",
"      </li>",
"      <li>",
"       Most cases develop after being bitten by an infected mosquito.",
"      </li>",
"      <li>",
"       Most people who contract WN virus do not develop any symptoms. Approximately 25 percent of people develop mild illness, called West Nile fever, which usually resolves spontaneously.",
"      </li>",
"      <li>",
"       A small number of infected people (about 1 in 230) develop severe or neuroinvasive disease, which affects the central nervous system and can result in permanent neurologic dysfunction or even death.",
"      </li>",
"      <li>",
"       There is no treatment for WN virus.",
"      </li>",
"      <li>",
"       The best way to avoid becoming infected is by preventing mosquito bites with repellents containing DEET, picaridin, oil of lemon eucalyptus, or IR3535 and by wearing protective clothing while outdoors. Pregnant or nursing women, people over age 50, and people who have received organ transplants or have other conditions that weaken the immune system are especially encouraged to take preventive measures.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804391979\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11569564\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=see_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/39/33395?source=see_link\">",
"      Patient information: Avoiding infections in pregnancy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11569598\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/52/43843?source=see_link\">",
"      Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=see_link\">",
"      Patient information: Blood donation and transfusion (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22264?source=see_link\">",
"      Clinical manifestations and diagnosis of West Nile virus infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16088?source=see_link\">",
"      Epidemiology and pathogenesis of West Nile virus infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=see_link\">",
"      Insect bites",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=see_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33958?source=see_link\">",
"      Treatment and prevention of West Nile virus infection",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Infectious Diseases Society of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.idsociety.org\">",
"      www.idsociety.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     UpToDate wishes to acknowledge Kelly Crowley for her contributions to this topic.",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?16/19/16690/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?16/19/16690?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16690/abstract/1\">",
"      Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001; 344:1807.",
"     </a>",
"    </li>",
"    <li>",
"     The United States Centers For Disease Control and Prevention file://cdc.gov/ncidod/dvbid/westnile/surv&amp;control.htm (Accessed on April 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16690/abstract/3\">",
"      O'Leary DR, Kuhn S, Kniss KL, et al. Birth outcomes following West Nile Virus infection of pregnant women in the United States: 2003-2004. Pediatrics 2006; 117:e537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16690/abstract/4\">",
"      Watson JT, Pertel PE, Jones RC, et al. Clinical characteristics and functional outcomes of West Nile Fever. Ann Intern Med 2004; 141:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16690/abstract/5\">",
"      Klee AL, Maidin B, Edwin B, et al. Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis 2004; 10:1405.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/ncidod/dvbid/westnile/RepellentUpdates.htm (Accessed on May 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16690/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Interim guidelines for the evaluation of infants born to mothers infected with West Nile virus during pregnancy. MMWR Morb Mortal Wkly Rep 2004; 53:154.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f16_19_16690=[""].join("\n");
var outline_f16_19_16690=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WEST NILE VIRUS RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           WEST NILE VIRUS TRANSMISSION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           WEST NILE VIRUS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WEST NILE VIRUS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WEST NILE VIRUS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WEST NILE VIRUS PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f16_19_16691="Fixed drug eruption arm";
var content_f16_19_16691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fixed drug eruption. An oval lesion occurred at the identical site where it had occurred previously. In both episodes, the rash emerged after this patient ingested a sulfonamide antibiotic. Note the eroded blister in the center of the lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16691=[""].join("\n");
var outline_f16_19_16691=null;
var title_f16_19_16692="IPH macrophages High";
var content_f16_19_16692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathology of idiopathic pulmonary hemosiderosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transbronchial lung biopsy from a 55-year-old woman with idiopathic pulmonary hemosiderosis and hemoptysis for six months. Combined staining for iron (Perls' Prussian blue) and nuclear counterstaining (Kernechtrot) demonstrates alveoli filled with hemosiderin-laden macrophages and thickening of the alveolar walls.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Per Praetorius Clausen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16692=[""].join("\n");
var outline_f16_19_16692=null;
var title_f16_19_16693="Glipizide: Patient drug information";
var content_f16_19_16693=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Glipizide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     see \"Glipizide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/39/10870?source=see_link\">",
"     see \"Glipizide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Glucotrol XL&reg;;",
"     </li>",
"     <li>",
"      Glucotrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to glipizide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703919",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: If you have a narrowing of the GI (gastrointestinal) tract or a bowel block.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem or type 1 diabetes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698205",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may see the tablet shell in your stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be used alone or with other high blood sugar (diabetes) drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705419",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Fast release:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before the first meal of the day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Long-acting products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695917",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with the first meal of the day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12511 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.202-D41C5C4F74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16693=[""].join("\n");
var outline_f16_19_16693=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176326\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013823\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013822\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013827\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013828\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013830\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013825\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013826\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013831\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013832\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=related_link\">",
"      Glipizide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/39/10870?source=related_link\">",
"      Glipizide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_19_16694="Basic case 11";
var content_f16_19_16694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1130px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Basic case 11",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 95px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16694=[""].join("\n");
var outline_f16_19_16694=null;
var title_f16_19_16695="Parinaud syndrome 2";
var content_f16_19_16695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parinaud syndrome (dorsal midbrain syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient has (A) bilateral lid retraction, pupillary dilatation; (B) the inability to look upward. The pupils do not react to light but do constrict to near effort.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology,&nbsp;2nd ed,&nbsp;Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16695=[""].join("\n");
var outline_f16_19_16695=null;
var title_f16_19_16696="Benazepril: Drug information";
var content_f16_19_16696=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benazepril: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/42/2726?source=see_link\">",
"    see \"Benazepril: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/5/40023?source=see_link\">",
"    see \"Benazepril: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lotensin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F139578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lotensin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F139611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F139582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension: Oral: Initial: 10 mg/day in patients not receiving a diuretic; 20-80 mg/day as a single dose or 2 divided doses; the need for twice-daily dosing should be assessed by monitoring peak (2-6 hours after dosing) and trough responses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients taking diuretics should have them discontinued 2-3 days prior to starting benazepril. If they cannot be discontinued, then initial dose should be 5 mg; restart after blood pressure is stabilized if needed.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F139599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/5/40023?source=see_link\">",
"      see \"Benazepril: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension: Children &ge;6 years: Oral: Initial: 0.2 mg/kg/day (up to 10 mg/day) as monotherapy; dosing range: 0.1-0.6 mg/kg/day (maximum dose: 40 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F139583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 5-10 mg/day in single or divided doses; usual range: 20-40 mg/day; adjust for renal function. Also see &ldquo;Note&rdquo; in adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F139584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Administer 5 mg/day initially; maximum daily dose: 40 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Moderately dialyzable (20% to 50%); administer dose postdialysis or administer 25% to 35% supplemental dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotensin&reg;: 10 mg, 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F139557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, either alone or in combination with other antihypertensive agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F139619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benazepril may be confused with Benadryl&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lotensin&reg; may be confused with Lioresal&reg;, lorcaserin, lovastatin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F139609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Postural dizziness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6%), dizziness (4%), somnolence (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine  increased (2%), worsening of renal function may occur in patients with bilateral renal artery stenosis or hypovolemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (1% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, alopecia, anaphylactoid reaction, angina, angioedema (includes head, neck and intestinal angioedema), arthralgia, arthritis, asthma, BUN increased (transient), dermatitis, dyspnea, ECG changes, eosinophilia, flushing, gastritis, hemolytic anemia, hyperbilirubinemia, hyperglycemia, hyperkalemia, hypersensitivity, hypertonia, hyponatremia, hypotension, impotence, insomnia, leukopenia, myalgia, neutropenia, orthostatic hypotension, palpitations, pancreatitis, paresthesia, pemphigus, peripheral edema, photosensitivity, proteinuria, pruritus, rash, shock, Stevens-Johnson syndrome, syncope, thrombocytopenia, transaminases increased, uric acid increased, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Eosinophilic pneumonitis, anaphylaxis, neutropenia, agranulocytosis, renal insufficiency, and renal failure have been reported with other ACE inhibitors. In addition, a syndrome including fever, myalgia, arthralgia, interstitial nephritis, vasculitis, rash, eosinophilia, and elevated ESR has been reported to be associated with ACE inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F139561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benazepril or any component of the formulation; patients with a history of angioedema (with or without prior ACE inhibitor therapy); concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F139545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema:  Any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Contraindicated in patients with history of angioedema with or without prior ACE inhibitor therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, with these agents and monitor potassium periodically.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE Inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes receiving insulin or oral antidiabetic agents; may be at increased risk for episodes of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F139550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrochlorothiazide: May enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F139573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Potassium supplements and/or potassium-containing salts may cause or worsen hyperkalemia. Management: Consult prescriber before consuming a potassium-rich diet, potassium supplements, or salt substitutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of benazepril (eg, shepherd&rsquo;s purse). Management: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F139551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F139564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Benazepril crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Their use in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F139587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6189081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of benazepril and benazeprilat are found in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F139563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Benazepril HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $105.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $105.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $105.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $105.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lotensin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $229.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $229.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $229.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2558446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum creatinine and potassium; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F139565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Benace (IN);",
"     </li>",
"     <li>",
"      Boncordin (AR);",
"     </li>",
"     <li>",
"      Cibacen (AE, AT, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CY, DE, DK, EG, ES, ET, GH, GM, GN, GR, GY, ID, IE, IL, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, NZ, OM, PH, PT, QA, SA, SC, SD, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Cibacene (FR);",
"     </li>",
"     <li>",
"      Labopal (ES);",
"     </li>",
"     <li>",
"      Lotensin (BR, CL, HN, HU, MX, PE, PL, RU, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F139544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibition of angiotensin I being converted to angiotensin II, a potent vasoconstrictor, through the angiotensin I-converting enzyme (ACE) activity, with resultant lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F139560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reduction in plasma angiotensin-converting enzyme (ACE) activity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: Peak effect: 1-2 hours after 2-20 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: &gt;90% inhibition for 24 hours after 5-20 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reduction in blood pressure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Single dose: 2-4 hours; Continuous therapy: 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid (37%); food does not alter significantly; metabolite (benazeprilat) itself unsuitable for oral administration due to poor absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~8.7 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benazepril: ~97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benazeprilat: ~95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly and extensively hepatic to its active metabolite, benazeprilat, via enzymatic hydrolysis; extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Benazeprilat: Effective: 10-11 hours; Terminal: Children: 5 hours, Adults: 22 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Parent drug: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urine (trace amounts as benazepril; 20% as benazeprilat; 12% as other metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Nonrenal clearance (ie, biliary, metabolic) appears to contribute to the elimination of benazeprilat (11% to 12%), particularly patients with severe renal impairment; hepatic clearance is the main elimination route of unchanged benazepril",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: ~6% of metabolite removed within 4 hours of dialysis following 10 mg of benazepril administered 2 hours prior to procedure; parent compound not found in dialysate",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, &ldquo;Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636. Available at  file://www.circulationaha.org/cgi/content/full/110/5/588",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox KM and EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators, &ldquo;Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients With Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study),&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):782-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/13678872/pubmed\" id=\"13678872\" target=\"_blank\">",
"        13678872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo;",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1997, 21(2):124-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/9201818/pubmed\" id=\"9201818\" target=\"_blank\">",
"        9201818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller DR, Oliveria SA, Berlowitz DR, et al, &ldquo;Angioedema Incidence in US Veterens Initiating Angiotensin-Converting Enzyme Inhibitors,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2008, 51(6):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/18413488/pubmed\" id=\"18413488\" target=\"_blank\">",
"        18413488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114 (2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al, &ldquo;Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(23):2312-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/10587334/pubmed\" id=\"10587334\" target=\"_blank\">",
"        10587334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, Greaves SC, Arnold JM, et al, &ldquo;Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction. The Healing and Early Afterload Reducing Therapy Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 95(12):2643-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/9193433/pubmed\" id=\"9193433\" target=\"_blank\">",
"        9193433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(20):1893-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/14610160/pubmed\" id=\"14610160\" target=\"_blank\">",
"        14610160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan A , &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo;",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/16427219/pubmed\" id=\"16427219\" target=\"_blank\">",
"        16427219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Sleight P, Pogue J, et al, &ldquo;Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/19/16696/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9081 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16696=[""].join("\n");
var outline_f16_19_16696=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708641\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139577\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139578\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139611\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139582\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139599\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139583\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139584\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673281\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139554\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139541\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139557\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139619\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139609\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139561\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139545\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298824\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139550\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139573\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139551\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139564\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139587\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6189081\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139563\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2558446\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139565\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139544\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139560\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9081\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9081|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/42/2726?source=related_link\">",
"      Benazepril: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/5/40023?source=related_link\">",
"      Benazepril: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_19_16697="Fracture classification one";
var content_f16_19_16697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 601px\">",
"   <div class=\"ttl\">",
"    Fracture classification: Part one",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 581px; height: 646px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Johnson, TR, Steinbach, LS (Eds): Essentials of Musculoskeletal imaging. Rosemonst, IL, American Academy of Orthopaedic Surgeons, 2004, p. 40-41. Copyright &copy;2004 American Academy of Orthopaedic Surgeons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16697=[""].join("\n");
var outline_f16_19_16697=null;
var title_f16_19_16698="Beta agonists in asthma: Controversy regarding chronic use";
var content_f16_19_16698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Beta agonists in asthma: Controversy regarding chronic use",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/19/16698/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/19/16698/contributors\">",
"     Robert F Lemanske, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/19/16698/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/19/16698/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/19/16698/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/19/16698/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/19/16698/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inhaled sympathomimetic is the bronchodilator of choice for treatment of an acute asthmatic attack [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, it is controversial whether these medications can be used safely for chronic maintenance therapy (monotherapy) or should be reserved for acute symptomatic control. Three arguments have been made against chronic use [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mortality may be increased",
"     </li>",
"     <li>",
"      Control of asthma may worsen",
"     </li>",
"     <li>",
"      Equal or superior efficacy can be achieved with inhaled glucocorticoids (corticosteroids)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the discussion that follows, \"short-acting\" beta agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ) are bronchodilators whose bronchodilator (but not bronchoprotective) effects last four to six hours. Long-acting beta agonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    ) are bronchodilators whose effects last 10 to 12 hours. \"Beta agonists\" refer to short-acting beta agonists if unspecified.",
"   </p>",
"   <p>",
"    Controversies surrounding the chronic use of beta agonists in patients with asthma will be reviewed here. The clinical use of beta agonists and an overview of asthma management are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=see_link&amp;anchor=H3#H3\">",
"     \"Beta agonists in asthma: Acute administration and prophylactic use\", section on 'Use in acute exacerbations of asthma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Short-acting beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between mortality in asthmatic patients and chronic treatment with beta agonists was initially suggested by several studies (all performed by the same investigative group) that used a cohort of 12,301 patients for whom asthma medications had been prescribed between 1978 and 1987 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an initial case-control study, 129 patients who had fatal or near&ndash;fatal asthmatic episodes (PaCO2 &gt;45 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intubation) were matched with 655 controls who had received asthma medications but had not had fatal or near&ndash;fatal events [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/3\">",
"       3",
"      </a>",
"      ]. An increased risk of death or near-death from asthma was associated with chronic use of inhaled beta agonist bronchodilators (odds ratio 1.9, 95% CI 1.6-2.4). The case-control design precluded the establishment of causality [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Information about asthma severity was subsequently gathered by questionnaire from the same 129 case patients and 655 control patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/6\">",
"       6",
"      </a>",
"      ]. Asthma severity was similar in the two groups, suggesting that the prior results were not confounded by asthma severity.",
"     </li>",
"     <li>",
"      In two retrospective cohort studies using all 12,301 patients, deaths due to asthma, cardiac causes, and all-causes were identified [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. The chronic use of inhaled beta agonist bronchodilators was associated with asthma-related death, but not all-cause mortality. Cardiac death was associated with oral and nebulized beta agonist use, but not beta agonist use via inhaler.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of six case&ndash;control studies found a weak association between death from asthma and nebulizer-delivered beta agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the association was so weak that its clinical significance was doubted.",
"   </p>",
"   <p>",
"    In a more recent and larger case-control study, 532 patients who died of asthma were compared to 532 control patients with a history of hospitalization for asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/10\">",
"     10",
"    </a>",
"    ]. There was no association between mortality and chronic beta-agonist use in the 4 to 12 months preceding death. However, mortality was associated with chronic beta agonist use one to five years prior to death (odds ratio 2.0, 95% CI 1.3-3.3), suggesting that a causal relationship was unlikely.",
"   </p>",
"   <p>",
"    Taken together, chronic short-acting beta agonist therapy, provided in conjunction with other asthma therapy, does not appear to have a large effect on mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Long-acting beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies have demonstrated the efficacy of chronic long-acting beta agonists (LABA) in improving pulmonary function, increasing symptom-free days, and decreasing the need for rescue beta agonists. However, there has been a controversy regarding the possibility of an association of chronic LABA treatment with severe exacerbations and increased mortality in a small subgroup of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/11-20\">",
"     11-20",
"    </a>",
"    ]. Although the association may be diminished or prevented by concomitant use of inhaled glucocorticoids, the data are not definitive [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Meta-analysis and clinical trial data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The controversy regarding the potential association of chronic LABA treatment with severe exacerbations and increased mortality is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis performed by the United States Food and Drug Administration (60,954 patients), an increased risk of serious asthma events (hospitalization, intubation, or death) was associated with LABA therapy versus no LABA (6.3 excess events per 1000 patient years, CI 2.2-10.3), particularly among the youngest patients aged 4 to 11 years [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/23\">",
"       23",
"      </a>",
"      ]. However, this increased risk was not seen in children and adolescents who also received inhaled glucocorticoids as an assigned study treatment. Conclusions regarding the protective effect of inhaled glucocorticoids are limited by the small number of patient events in this subgroup.",
"     </li>",
"     <li>",
"      A systematic review and meta-analysis assessed the impact of LABA (either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      ), taken for at least 12 weeks, on asthma-related total morbidity and mortality among patients concomitantly using inhaled glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/15\">",
"       15",
"      </a>",
"      ]. The search of MEDLINE, EMBASE, ACPJC, and Cochrane (Central) databases yielded 62 relevant blinded, randomized trials with over 29,000 participants (15,710 taking LABA and over 8,000 patient-years observed in the LABA groups). Three asthma-related deaths and two asthma-related, nonfatal intubations (all in LABA groups; &le;1 event per study) occurred. The OR for total mortality was 1.26 (95% CI 0.58-2.74), reflecting 14 deaths in LABA groups and eight deaths in control groups, respectively. Differences in asthma-related hospitalizations (OR, 0.74; 95% CI 0.53-1.03) and asthma-related serious adverse events (mostly hospitalizations; OR, 0.75; 95% CI 0.54-1.03) failed to reach statistical significance. There were very few asthma-related deaths and intubations, and events were too infrequent to establish LABA's relative effect on these outcomes.",
"     </li>",
"     <li>",
"      A meta-analysis of 66 trials (20,966 participants) comparing the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/33/26136?source=see_link\">",
"       fluticasone-salmeterol",
"      </a>",
"      with inhaled glucocorticoid alone found that combination therapy was associated with a decrease in the risk of severe exacerbation, no change in the risk of hospitalization, and no apparent increase in the risk of intubation or death [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/14\">",
"       14",
"      </a>",
"      ]. The study population differed from that of the SMART trial described above in that participants were in closely supervised clinical trials.",
"     </li>",
"     <li>",
"      A meta-analysis of all AstraZeneca randomized trials involving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      and lasting more than 12 weeks found only 10 deaths in a combined study population of 68,004 patients with asthma (23,600 person years of exposure to formoterol) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/17\">",
"       17",
"      </a>",
"      ]. The adjusted death rate among patients taking formoterol was not significantly increased (RR 2.68; 95% CI 0.53-13.5), although the confidence intervals were broad. Formoterol was associated with a significant reduction in asthma-related nonfatal severe adverse events. No increase in the rate of serious adverse events was noted with increasing doses of formoterol. Despite the size of the combined study population, the meta-analysis did not have the power to conclude absolutely that formoterol is not associated with an increase in mortality risk.",
"     </li>",
"     <li>",
"      In a systematic review of trials that compared regular treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      plus inhaled glucocorticoid to salmeterol alone, 11 deaths occurred in the combined study population of 10,873 asthma patients and none were reported to be asthma-related [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/21\">",
"       21",
"      </a>",
"      ]. The number of patients experiencing adverse events was too small to definitively exclude the possibility of an increase in risk related to salmeterol, although there was no significant difference in fatal or non-fatal serious adverse events between the two groups.",
"     </li>",
"     <li>",
"      In a randomized trial, more than 25,000 patients with asthma were assigned to receive the long-acting beta agonist,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      , or the short-acting beta agonist,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/11\">",
"       11",
"      </a>",
"      ]. There was a nonstatistically significant three-fold increased likelihood of death among patients that received salmeterol (12 of 16,787) compared to patients that received albuterol (2 of 8393). Interpretation of the study was limited by bias due to higher withdrawal from the albuterol group and by inability to evaluate subgroups that did or did not receive inhaled glucocorticoids.",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       Salmeterol",
"      </a>",
"      Multicenter Asthma Research Trial (SMART) was a randomized trial in which 26,355 patients with asthma were assigned to receive salmeterol or placebo for 28 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/12\">",
"       12",
"      </a>",
"      ]. Salmeterol use was associated with increased respiratory-related death (relative risk 2.2, 95% CI 1.1-4.4), asthma-related death (relative risk 4.4, 95% CI 1.2-15.3), and combined asthma-related death or life-threatening experience (relative risk 1.7, 95% CI 1.0-2.9). Subgroup analysis suggested that the risk might be greater in African Americans. Like the trial above, SMART was not designed to evaluate subgroups that did or did not receive inhaled glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interpretation of these and other data is complicated, particularly regarding the impact of concurrent inhaled glucocorticoids. Many experts believe that inhaled glucocorticoids diminish or prevent the potential risk of long-acting beta agonists, while others believe the data are insufficient to warrant this conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. However, despite these potential risks in small numbers of patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    in combination with inhaled glucocorticoids significantly reduces exacerbation rates in the majority of adults. Thus, as with all medications, the proper balance between risk and benefit with combination therapy should be individually evaluated and prospectively monitored over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Formoterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alternative long-acting beta agonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    , has not been as well studied as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    . In a meta-analysis of 22 studies (8032 participants), an increase in serious adverse events (SAEs) was noted when regular use of formoterol was compared with placebo (OR 1.57, 95% CI 1.06 to 2.31), but not when compared with regular use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/27\">",
"     27",
"    </a>",
"    ]. Overall, nonfatal SAEs were rare, occurring in 1 percent of patients on placebo. Too few asthma-related deaths were reported to assess drug-related mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies conducted by the NHLBI-funded Asthma Clinical Research Network have demonstrated that monotherapy with LABAs increases the risk of asthma exacerbations and treatment failure in patients previously receiving inhaled glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. These data, along with the results observed in the SMART trial described above [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/12\">",
"     12",
"    </a>",
"    ], in which many patients were receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    monotherapy and experienced adverse outcomes, strongly indicate that LABAs should not be used as monotherapy. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Monotherapy switch'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether the concomitant administration of inhaled glucocorticoids attenuates or mitigates the adverse effects attributed to LABA therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/30\">",
"     30",
"    </a>",
"    ]. This uncertainty is related to results of studies in which the LABA and inhaled glucocorticoid were administered using separate inhaler devices as opposed to fixed dose combination inhalers that contain both in one device. Thus, additional research is needed to resolve the questions whether LABA therapy is associated with an increased risk of severe or fatal asthma exacerbations and whether associated inhaled glucocorticoid therapy is fully protective [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/14,16,31,32\">",
"     14,16,31,32",
"    </a>",
"    ]. Unfortunately, the formidable sample size that would be required makes it highly unlikely that such a trial will be possible [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/18,33\">",
"     18,33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     FDA advisory statement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Food and Drug Administration (FDA) has mandated that a \"black box\" warning label be added to all products containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/59/26549?source=see_link\">",
"     indacaterol",
"    </a>",
"    because of \"an increased risk of severe exacerbation of asthma symptoms, leading to hospitalizations, in pediatric and adult patients, as well as death in some patients using LABAs for the treatment of asthma.\"",
"   </p>",
"   <p>",
"    The FDA warning advises that the use of a LABA as monotherapy without the concomitant use of a long-term asthma control medication, such as an inhaled glucocorticoid, is contraindicated in the treatment of asthma. In addition, the FDA advises that LABAs should only be used as additional therapy for patients with asthma who are currently taking a long-term asthma control medication, such as an inhaled glucocorticoid, but are not adequately controlled. Once asthma control is achieved and maintained, step-down therapy is advised, with discontinuation of the LABA if possible without loss of asthma control. For pediatric and adolescent patients who require the addition of a LABA to an inhaled glucocorticoid, the FDA advises that a combination product containing both of these medications be used. Additional information is available online: (",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213836.htm\">",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213836.htm",
"    </a>",
"    ), or by telephone (888-INFO-FDA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3905123\">",
"    <span class=\"h3\">",
"     National Asthma Education and Prevention Program (III)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on a thorough review of the literature regarding safety and efficacy of long acting beta agonists, the National Asthma Education and Prevention Program (NAEPP) expert panel recommended various options for Step 3 care in both children and adults with asthma whose disease was not well controlled on low doses of inhaled glucocorticoids (ICS) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/1\">",
"     1",
"    </a>",
"    ]. One choice consisted of the addition of a LABA, the other choice an increase in the inhaled glucocorticoid dose to the medium range. Following the release of the 2010 FDA advisory statement outlined above, members of the NAEPP expert panel did not feel that any data generated from the time of their report in 2007 to the release of the 2010 FDA advisory statement would change the 2007 recommendations or the interpretation of the data that led to them [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ASTHMA CONTROL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Regular versus as-needed administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current recommendation of the National Asthma Education and Prevention Program expert panel report is to prescribe short acting beta agonists as needed for symptom control rather than on a regular schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/1\">",
"     1",
"    </a>",
"    ]. This recommendation is made despite most rigorously designed trials suggesting that beta agonists administered on a regular schedule compared to an \"as-needed\" schedule do not lead to worsening asthma control or increased complications. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 255 patients with mild asthma (FEV1 &ge;70 percent of the predicted value, PC20 &lt;16",
"      <span class=\"nowrap\">",
"       mg/ml,",
"      </span>",
"      infrequent use of inhaled beta agonists, and no glucocorticoid use within 6 weeks) were assigned to receive inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      on a regular basis plus albuterol as-needed or placebo inhaled on a regular basis plus albuterol as-needed for 16 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/35\">",
"       35",
"      </a>",
"      ]. There was no difference in asthma exacerbations, treatment failures, lung function, asthma symptoms, peak flow variability, or PC20.",
"     </li>",
"     <li>",
"      In a similar randomized trial of 983 patients, those assigned to receive regularly scheduled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      for 12 months did not have an increased rate of exacerbations compared to those randomized to receive placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, diminution of the \"bronchoprotective effect\" is an important adverse outcome found when patients use beta agonists on a regular schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/37\">",
"     37",
"    </a>",
"    ]. The bronchoprotective effect is described as the ability to protect against bronchoconstriction in response to chemical stimuli (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    ), exercise, or allergen exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/38-43\">",
"     38-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the clinical significance of this diminution has been debated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/44\">",
"     44",
"    </a>",
"    ], the change in bronchoprotective effect following allergen challenge is associated with an enhancement of the late asthmatic response, an increase in the number of sputum eosinophils, and release of eosinophil mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decreased bronchoprotective effect associated with the chronic use of beta agonists may be related to a process termed \"desensitization\" (ie, decreased cellular responsiveness due to exposure to a continuous stimulus). The mechanisms of desensitization of beta 2-adrenoceptors (and other G protein-coupled receptors) include rapid (minutes) alterations such as receptor phosphorylation (by protein kinase A or C",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    G protein-coupled receptor kinases), uncoupling of the receptor from its attached G protein,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sequestration. Slower changes may involve increased receptor degradation and decreased receptor synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=see_link\">",
"     \"Beta-2 adrenergic receptor dysfunction and polymorphism in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intermediate-acting beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized, crossover study, 89 patients with stable asthma were assigned to receive regularly scheduled intermediate-acting beta agonist (fenoterol) plus as-needed short-acting beta agonist or regularly scheduled placebo plus as-needed short-acting beta agonist [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/4\">",
"     4",
"    </a>",
"    ]. Of 64 subjects who completed the trial, 17 patients (27 percent) had better asthma control during regularly scheduled fenoterol treatment, 40 patients (62 percent) had better asthma control during regularly scheduled placebo treatment, and 7 patients (11 percent) had equal asthma control regardless of the medication. The median time from the commencement of each treatment period to the first exacerbation was 33 days with regularly scheduled therapy versus 66 days with as needed use (",
"    <a class=\"graphic graphic_figure graphicRef57179 \" href=\"UTD.htm?1/50/1838\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In two subsequent reports from the same investigators, using the same cohort of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regularly scheduled fenoterol was associated with more exacerbations and an increase in airway responsiveness to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      ; there was, however, no alteration in bronchodilator responsiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subsequent analysis, the deleterious responses noted following chronic beta agonist were not related to beta-2 receptor polymorphisms [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=see_link\">",
"       \"Beta-2 adrenergic receptor dysfunction and polymorphism in asthma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these reports, a number of trials have not corroborated the deleterious effects of intermediate-acting beta agonists in the short-term [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/50,51\">",
"     50,51",
"    </a>",
"    ] or the long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/52-54\">",
"     52-54",
"    </a>",
"    ], as measured by peak expiratory flow rate or symptom control (",
"    <a class=\"graphic graphic_figure graphicRef78242 \" href=\"UTD.htm?37/25/38302\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Long&ndash;acting beta-agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of LABA therapy on asthma control has been examined during short-term and long-term use. In studies looking at short-term administration of long-acting beta agonist monotherapy, the long-acting beta agonists demonstrated prolonged bronchodilation and protection from bronchoprovocation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of chronic administration of long-acting beta agonists have also been evaluated. In a randomized trial, 234 patients were assigned to receive regularly scheduled long-acting beta-agonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ), short-acting beta agonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/52\">",
"     52",
"    </a>",
"    ]. Salmeterol was more effective at increasing the morning peak expiratory flow rate than albuterol or placebo (+24, -6, +1",
"    <span class=\"nowrap\">",
"     L/min,",
"    </span>",
"    respectively). The mean overall symptom score was improved most by salmeterol treatment, with the number of days with symptoms and of nights with awakenings decreasing by 22 percent and 52 percent, respectively. There was no evidence of tolerance to the bronchodilating effects of salmeterol.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    use in the above study failed to show tolerance to the bronchodilating effects of salmeterol, other studies demonstrated that salmeterol induced tolerance to the bronchodilating effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The effect was mediated by beta-2 adrenoceptor downregulation and bronchodilator desensitization to albuterol.",
"   </p>",
"   <p>",
"    Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    appears to induce tolerance to the bronchodilating effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    . In one study, 10 patients with stable asthma were given scheduled formoterol for durations ranging from a single dose to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/59\">",
"     59",
"    </a>",
"    ]. The patients were then exposed to a bronchoconstrictor stimulus (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    ) and their bronchodilator response to albuterol was measured. Bronchodilator tolerance occurred after one dose of formoterol and progressively increased up to one week. Tolerance resolved three days after discontinuation of the formoterol.",
"   </p>",
"   <p>",
"    Tolerance to protection against a bronchoconstrictor stimulus has also been studied. As an example, 24 patients with mild asthma were randomly assigned to receive treatment with inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    or placebo. The bronchodilatory effects of salmeterol did not change but protection against a bronchoconstrictor stimulus (inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    ) declined from a 10-fold increase to a two-fold increase in the dose of methacholine required to produce a 20 percent fall in FEV1 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Taken together, the data suggest that chronic long-acting beta agonists improve pulmonary function and asthma symptoms. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    induce tolerance to the bronchodilating effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    , the clinical significance of the tolerance remains speculative [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Indeed, one study demonstrated that, despite the development of a loss of bronchoprotection, no loss of asthma control occurred as measured by respiratory symptoms, rescue beta agonist use, and baseline FEV1 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tolerance induced by chronic use of long-acting beta agonists may contribute to the association of chronic long-acting beta agonists with serious adverse events and mortality as discussed above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Long-acting beta agonists'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10936292\">",
"    <span class=\"h2\">",
"     Impact of race",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a post hoc analysis of clinical trials published by the NHLBI-funded Asthma Clinical Research Network, African American patients taking LABA were more likely to experience treatment failure than white patients taking LABA (OR 2.1, 95% CI 1.3&ndash;3.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/65\">",
"     65",
"    </a>",
"    ]. Treatment failure was defined as an increase in systemic or inhaled glucocorticoid use, hospitalizations, emergency visits,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    use, or a prolonged decrease in peak expiratory flow, although most of the treatment failures were due to increased albuterol use. At baseline, African-American patients reported fewer asthma symptoms and less rescue beta-agonist use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Beta receptor polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of polymorphic forms of the beta-2 adrenergic receptor were described in 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/66\">",
"     66",
"    </a>",
"    ]. The potential role of beta-2 adrenergic receptor dysfunction in the pathogenesis of asthma and in individual responses to beta agonists is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=see_link\">",
"     \"Beta-2 adrenergic receptor dysfunction and polymorphism in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     BETA AGONISTS VERSUS INHALED GLUCOCORTICOIDS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Direct comparison",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advocates for inhaled glucocorticoids (corticosteroids) argue that chronic beta agonist therapy may be harmful by providing symptom relief while permitting the underlying inflammatory process to progress. It is unclear whether this is true as some studies reveal decreased inflammation associated with chronic beta agonist therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/67,68\">",
"     67,68",
"    </a>",
"    ] while others do not [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/69\">",
"     69",
"    </a>",
"    ]. Conversely, advocates for chronic beta agonist therapy describe adverse effects associated with inhaled glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Although some studies found no difference when inhaled glucocorticoids were compared to monotherapy with long-acting beta agonists (LABA) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/70\">",
"     70",
"    </a>",
"    ], most studies favored inhaled glucocorticoids over chronic beta agonist therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/53,71\">",
"     53,71",
"    </a>",
"    ]. This is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 103 patients with newly detected asthma were assigned to receive inhaled glucocorticoid (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      ) or chronic beta agonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/53\">",
"       53",
"      </a>",
"      ]. Budesonide was more effective at reducing symptoms, decreasing rescue beta agonist administration, and improving peak expiratory flow rate (PEFR).",
"     </li>",
"     <li>",
"      In a separate trial, 241 children with asthma were randomly assigned to receive a chronic long-acting beta agonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      ), an inhaled glucocorticoid (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      ), or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/71\">",
"       71",
"      </a>",
"      ]. Beclomethasone was associated with decreased airway responsiveness to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      , decreased need for rescue beta agonist, and fewer asthma exacerbations compared to salmeterol or placebo. Both beclomethasone and salmeterol were associated with less variability of PEFR compared to placebo. Linear growth was impaired in the children receiving beclomethasone, but not salmeterol or placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Monotherapy switch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conversion from inhaled glucocorticoid monotherapy to chronic long-acting beta agonist monotherapy in adult patients cannot be performed without loss of asthma control, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a controlled trial, 164 patients with mild asthma received inhaled glucocorticoid (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      ) for six weeks, and then were randomly assigned to receive long-acting beta agonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      ), triamcinolone, or placebo for 16 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/28\">",
"       28",
"      </a>",
"      ]. No differences were detected between the salmeterol and triamcinolone groups for peak expiratory flow rate, asthma symptom scores, rescue beta agonist use, or quality of life scores. Both were superior to placebo. However, the salmeterol group had more treatment failures (24 versus 6 percent) and asthma exacerbations (20 versus 7 percent) than the triamcinolone group.",
"     </li>",
"     <li>",
"      In another controlled trial, 175 patients with persistent asthma that was suboptimally controlled during a 6-week period of treatment with inhaled glucocorticoid (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide) were randomly assigned to have placebo or long-acting beta agonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      ) added [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/29\">",
"       29",
"      </a>",
"      ]. In the group receiving salmeterol, a dose reduction of inhaled glucocorticoid by 50 percent was not associated with any significant increase in treatment failure. However, complete elimination of the inhaled glucocorticoid led to a significant increase in treatment failure rates (46 versus 14 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, as discussed above, monotherapy with a LABA is not advised. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Monotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combining chronic beta agonists with inhaled glucocorticoids is an attractive therapeutic option. In theory, the inhaled glucocorticoid should suppress the underlying inflammatory response while the chronic beta agonist provides enough symptom control to permit lower doses of the inhaled glucocorticoid to be used, thus reducing glucocorticoid-related adverse effects. Herein, \"combination therapy\" refers inhaled glucocorticoids plus long-acting inhaled beta agonist. We follow the National Asthma Education and Prevention Program expert panel report III regarding the specific indications for adding a LABA for the treatment of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/1,34\">",
"     1,34",
"    </a>",
"    ]. These recommendations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of moderate persistent asthma in adolescents and adults\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approaching an evaluation of efficacy, it is important to note that inhaled glucocorticoid monotherapy versus combination therapy may differentially affect various outcome measures. As an example, one treatment may be better at improving pulmonary function, while both may be equally good at controlling exacerbations. Thus, the choice of therapy may depend on which outcome needs greater control in an individual patient. In addition, the patient's current medication regimen should be considered (eg, receiving or not receiving controller medications).",
"   </p>",
"   <p>",
"    In glucocorticoid na&iuml;ve patients with mild airway obstruction, the initiation of combination therapy does not reduce the rate of exacerbations compared to initiation of inhaled glucocorticoids alone. Combination therapy does improve lung function and symptom-free days, but does not reduce use of short-acting inhaled beta agonists as a rescue medication compared to inhaled glucocorticoids alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Thus, there is insufficient evidence to recommend combination therapy for patients with mild persistent asthma who have not previously received inhaled glucocorticoids (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Similar findings regarding overall greater clinical efficacy using monotherapy with inhaled glucocorticoids versus combination therapy with inhaled glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    have been reported in school age children and adolescents with mild to moderate persistent asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients already receiving low to high doses of inhaled glucocorticoids and whose asthma is not well controlled, two meta-analyses have compared low to high-dose inhaled glucocorticoid monotherapy versus combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first meta-analysis examined 26 randomized, controlled trials that compared the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      versus placebo to inhaled glucocorticoids. The meta-analysis found that the addition of a daily long-acting beta agonist reduced the risk of exacerbations requiring systemic glucocorticoids by 19 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/75\">",
"       75",
"      </a>",
"      ]. Furthermore, the addition of a long-acting beta agonist improved FEV1, the number of symptom-free days, and the number of days in which rescue short-acting beta agonists were required. A similar number of serious adverse events and withdrawal rates occurred in both groups.",
"     </li>",
"     <li>",
"      Another meta-analysis examined 30 randomized, controlled trials (9509 patients) that compared increasing the dose of inhaled glucocorticoid versus keeping the dose constant and adding a long-acting beta agonist. There was improvement in FEV1 (WMD 100 mL, 95% CI 0.77-1.02 L), symptom-free days (WMD 11.9 percent, 95% CI 7.4-16.4 percent), and use of rescue beta agonist (WMD -1.0",
"      <span class=\"nowrap\">",
"       puffs/day,",
"      </span>",
"      95% CI -1.41 to -0.58",
"      <span class=\"nowrap\">",
"       puffs/day)",
"      </span>",
"      in the combination therapy group compared to the monotherapy group [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/74\">",
"       74",
"      </a>",
"      ]. There was no difference in the incidence of exacerbations requiring systemic glucocorticoids (relative risk 0.88, 95% CI 0.77-1.02), the overall adverse events (relative risk 0.93, 95% CI 0.84-1.03), or side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies similarly found low-dose inhaled glucocorticoid plus chronic long-acting beta agonist combination therapy to be superior to high-dose inhaled glucocorticoid monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/76-81\">",
"     76-81",
"    </a>",
"    ]. It is important to emphasize that the number of patients enrolled in these trials was insufficient to determine if the results observed in adults similarly apply to pediatric patients. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Step-up therapy in children and adolescents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Two major studies evaluated combination therapy using novel therapeutic approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first trial (the GOAL study) evaluated whether aggressive escalation of therapy (until total control or maximum dose inhaled glucocorticoids) affects asthma control [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/82\">",
"       82",
"      </a>",
"      ]. In the GOAL study, 3421 patients with asthma were randomly assigned to receive inhaled glucocorticoid (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      ) or inhaled glucocorticoid (fluticasone) plus long-acting beta agonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      ). More patients achieved total asthma control with",
"      <span class=\"nowrap\">",
"       salmeterol/fluticasone",
"      </span>",
"      than fluticasone monotherapy both immediately after escalation (31 versus 19 percent) and one year later (41 versus 28 percent). In addition, control was achieved more rapidly and at a lower glucocorticoid dose with",
"      <span class=\"nowrap\">",
"       salmeterol/fluticasone",
"      </span>",
"      than fluticasone alone.",
"     </li>",
"     <li>",
"      The second trial (the STAY study) evaluated whether a combination drug (inhaled glucocorticoid plus long-acting beta agonist) could serve as both maintenance therapy and as a rescue inhaler [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/83\">",
"       83",
"      </a>",
"      ]. Since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      has a rapid onset of action, the investigators hypothesized that patients receiving maintenance dose",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"        budesonide",
"       </a>",
"       /formoterol",
"      </span>",
"      would benefit from replacement of their short-acting beta-2-agonist (SABA) rescue medication with as-needed",
"      <span class=\"nowrap\">",
"       budesonide/formoterol",
"      </span>",
"      due to rapid symptom relief and simultaneous increase in anti-inflammatory therapy.",
"      <br/>",
"      <br/>",
"      In the STAY trial, 2760 patients with asthma were randomly assigned to receive rescue plus maintenance",
"      <span class=\"nowrap\">",
"       budesonide/formoterol,",
"      </span>",
"      rescue",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      plus maintenance",
"      <span class=\"nowrap\">",
"       budesonide/formoterol,",
"      </span>",
"      or rescue terbutaline plus maintenance budesonide [",
"      <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/83\">",
"       83",
"      </a>",
"      ]. The group receiving",
"      <span class=\"nowrap\">",
"       budesonide/formoterol",
"      </span>",
"      for both rescue and maintenance had prolonged time to first severe exacerbation, lower exacerbation risk, improved symptoms, fewer awakenings, and better lung function compared to the other groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Glucocorticoid-sparing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A glucocorticoid-sparing effect refers to the ability of a pharmacologic agent to permit inhaled glucocorticoid dose reduction following its addition to a preexisting inhaled glucocorticoid regimen. The efficacy of chronic LABAs as glucocorticoid-sparing agents has been studied. This was best illustrated in a meta-analysis of 10 randomized, controlled trials comparing high-dose inhaled glucocorticoid versus combined low-dose inhaled glucocorticoid plus chronic long-acting beta agonist [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/84\">",
"     84",
"    </a>",
"    ]. Addition of a chronic long-acting beta agonist permitted 37 to 60 percent reduction of the inhaled glucocorticoid dose without deterioration of asthma control.",
"   </p>",
"   <p>",
"    Other studies have confirmed the efficacy of long-acting beta agonists as glucocorticoid-sparing agents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/80,85\">",
"     80,85",
"    </a>",
"    ]. Tapering of the inhaled glucocorticoid was associated with increased sputum eosinophils in one study, but this was not accompanied by increased symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Step-up therapy in children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of three treatment regimens as step-up treatment was evaluated in children and adolescents whose asthma was not well-controlled on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    100 mcg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/86\">",
"     86",
"    </a>",
"    ]. Adding a LABA was 1.6 times as likely as adding a leukotriene receptor antagonist (LTRA) and 1.7 times as likely as increasing the inhaled glucocorticoid to result in improved asthma control. However, some children demonstrated their best response to ICS or LTRA step-up rather than to the LABA, highlighting the need to regularly monitor and appropriately adjust each child's asthma therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link&amp;anchor=H27#H27\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3905193\">",
"    <span class=\"h3\">",
"     Step-down therapy following establishment of control on combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the FDA advisory statement that led to the new black box warnings on drugs containing LABAs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/87\">",
"     87",
"    </a>",
"    ], the FDA recommended that, once asthma control is achieved and maintained, therapy should be stepped down with discontinuation of the LABA if possible without loss of asthma control. However, a number of published studies have questioned the rationale of choosing to eliminate the LABA once control is satisfactorily achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/88-91\">",
"     88-91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Potential risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains unclear whether the combination of an inhaled glucocorticoid and a long-acting beta agonist (LABA) carries an increased risk of catastrophic asthma events or death compared with an inhaled glucocorticoid alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/19,92,93\">",
"     19,92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis examined data from 42 clinical trials that included a total of 23,510 patients randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    plus an inhaled glucocorticoid or an inhaled glucocorticoid alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/19\">",
"     19",
"    </a>",
"    ]. No asthma-related deaths and one asthma-related intubation occurred. Asthma related hospitalizations were lower in the formoterol plus inhaled glucocorticoid group (RR 0.79; 95% CI, 0.54-1.01). A similar meta-analysis of formoterol safety data from 68,004 patients reported eight asthma-related deaths among 49,906 formoterol-treated patients and two among 18,098 non-formoterol treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/17\">",
"     17",
"    </a>",
"    ]. However, this larger study included 10 asthma-related deaths that occurred in open-label trials, in trials without a non-LABA control arm, after the end of randomized treatment, or were later adjudicated as non-asthma-related.",
"   </p>",
"   <p>",
"    A separate meta-analysis examined clinical trial data from 4039 patients treated with a LABA plus an inhaled glucocorticoid compared with 3214 patients treated with an inhaled glucocorticoid without a LABA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/92\">",
"     92",
"    </a>",
"    ]. A statistically significant increase in the risk of an asthma-related intubation or death was noted in the LABA-treated group. However, methodologic issues limit the interpretation of this meta-analysis. Only trials that included at least one event were included; the use of inhaled glucocorticoids was not necessarily controlled; and the dose of inhaled glucocorticoids varied between the LABA plus inhaled glucocorticoid and the inhaled glucocorticoid alone groups.",
"   </p>",
"   <p>",
"    The potential benefits and risks of adding a LABA to an inhaled glucocorticoid in a patient whose asthma is not well-controlled on inhaled glucocorticoid alone need further study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/34\">",
"     34",
"    </a>",
"    ]. In the meantime, we follow the step-wise approach to asthma outlined in National Asthma Education and Prevention Program [",
"    <a class=\"abstract\" href=\"UTD.htm?16/19/16698/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic short-acting beta agonists, provided in conjunction with other asthma therapy, do not have a large effect on mortality. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Short-acting beta agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic long-acting beta agonists (LABA) are efficacious in improving pulmonary function, increasing symptom-free days, and decreasing the need for rescue beta agonists. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Direct comparison'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Long-acting beta agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Beta agonists administered on a regular schedule compared to an \"as needed\" schedule do not worsen asthma control or increase complications in most patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Regular versus as-needed administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       Salmeterol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      may induce tolerance to the bronchodilating effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      . In addition, the protective effect of salmeterol against a bronchoconstrictor stimulus is reduced with chronic use. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Long&ndash;acting beta-agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the beneficial effects of LABA, there has been a controversy over whether chronic use of long-acting beta agonists may be associated with rare severe asthma exacerbations and increased asthma and cardiac mortality in a small subgroup of patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Long-acting beta agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long acting beta agonists should NOT be prescribed as monotherapy for asthma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Monotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'FDA advisory statement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conversion from inhaled glucocorticoid monotherapy to chronic long-acting beta agonist monotherapy can result in loss of asthma control and is NOT advised. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Monotherapy switch'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients na&iuml;ve to inhaled glucocorticoids (also known as inhaled corticosteroids or ICS) therapy and requiring a controller medication for mild persistent asthma (eg, Step 2 care based on guideline recommendations), monotherapy with inhaled glucocorticoids rather than combination therapy with both ICS and LABA is advised as first line therapy (",
"      <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We follow the National Asthma Education and Prevention Program expert panel report III guidelines regarding the specific indications for adding a LABA for the treatment of asthma. These recommendations are discussed separately. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Combination therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"       \"An overview of asthma management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=see_link&amp;anchor=H24#H24\">",
"       \"Treatment of moderate persistent asthma in adolescents and adults\", section on 'Summary and recommendations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=see_link&amp;anchor=H29#H29\">",
"       \"Treatment of severe asthma in adolescents and adults\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic long-acting beta agonist therapy has the potential to permit inhaled glucocorticoid dose reductions (ie, they are glucocorticoid-sparing). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies are insufficient to conclude whether inhaled glucocorticoids are protective against any potential increase in mortality related to chronic LABA use. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Long-acting beta agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving long-acting beta agonists should be monitored closely and advised of the reported increased risk noted in a small number of patients and of the importance of seeking medical care if their symptoms persist or worsen. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Long-acting beta agonists'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. Full text available online at: file://www.ginasthma.com (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/3\">",
"      Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/4\">",
"      Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/5\">",
"      O'Byrne PM, Kerstjens HA. Inhaled beta 2-agonists in the treatment of asthma. N Engl J Med 1996; 335:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/6\">",
"      Ernst P, Habbick B, Suissa S, et al. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis 1993; 148:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/7\">",
"      Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/8\">",
"      Suissa S, Hemmelgarn B, Blais L, Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996; 154:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/9\">",
"      Mullen M, Mullen B, Carey M. The association between beta-agonist use and death from asthma. A meta-analytic integration of case-control studies. JAMA 1993; 270:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/10\">",
"      Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005; 330:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/11\">",
"      Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/12\">",
"      Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/13\">",
"      Walters EH, Gibson PG, Lasserson TJ, Walters JA. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007; :CD001385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/14\">",
"      Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008; 149:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/15\">",
"      Jaeschke R, O'Byrne PM, Mejza F, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med 2008; 178:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/16\">",
"      Martinez FD. Safety of long-acting beta-agonists--an urgent need to clear the air. N Engl J Med 2005; 353:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/17\">",
"      Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/18\">",
"      Wijesinghe M, Weatherall M, Perrin K, et al. Risk of mortality associated with formoterol: a systematic review and meta-analysis. Eur Respir J 2009; 34:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/19\">",
"      Nelson H, Bonuccelli C, Radner F, et al. Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials. J Allergy Clin Immunol 2010; 125:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/20\">",
"      de Vries F, Setakis E, Zhang B, van Staa TP. Long-acting {beta}2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD. Eur Respir J 2010; 36:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/21\">",
"      Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2013; 3:CD006922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/22\">",
"      Malone R, LaForce C, Nimmagadda S, et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 2005; 95:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/23\">",
"      McMahon AW, Levenson MS, McEvoy BW, et al. Age and risks of FDA-approved long-acting &beta;���-adrenergic receptor agonists. Pediatrics 2011; 128:e1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/24\">",
"      O'Byrne PM, Adelroth E. Beta2 d&eacute;j&agrave; vu. Chest 2006; 129:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/25\">",
"      Nelson HS. Is there a problem with inhaled long-acting beta-adrenergic agonists? J Allergy Clin Immunol 2006; 117:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/26\">",
"      Ernst P, McIvor A, Ducharme FM, et al. Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006; 145:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/27\">",
"      Cates CJ, Cates MJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2012; 4:CD006923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/28\">",
"      Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285:2583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/29\">",
"      Lemanske RF Jr, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001; 285:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/30\">",
"      Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008; :CD006363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/31\">",
"      Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/32\">",
"      Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 2009; 360:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/33\">",
"      Sears MR. Safety of long-acting beta-agonists: are new data really required? Chest 2009; 136:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/34\">",
"      Lemanske RF Jr, Busse WW. The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy? J Allergy Clin Immunol 2010; 126:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/35\">",
"      Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/36\">",
"      Dennis SM, Sharp SJ, Vickers MR, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 2000; 355:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/37\">",
"      Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 2004; 140:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/38\">",
"      Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/39\">",
"      Gibson GJ, Greenacre JK, K&ouml;nig P, et al. Use of exercise challenge to investigate possible tolerance to beta-adrenoceptor stimulation in asthma. Br J Dis Chest 1978; 72:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/40\">",
"      Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/41\">",
"      Cockcroft DW, Swystun VA, Bhagat R. Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med 1995; 152:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/42\">",
"      Bhagat R, Swystun VA, Cockcroft DW. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. J Allergy Clin Immunol 1996; 97:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/43\">",
"      Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997; 99:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/44\">",
"      McFadden ER Jr. Perspectives in beta 2-agonist therapy: vox clamantis in deserto vel lux in tenebris? J Allergy Clin Immunol 1995; 95:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/45\">",
"      Gauvreau GM, Jordana M, Watson RM, et al. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med 1997; 156:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/46\">",
"      Penn RB, Panettieri RA Jr, Benovic JL. Mechanisms of acute desensitization of the beta2AR-adenylyl cyclase pathway in human airway smooth muscle. Am J Respir Cell Mol Biol 1998; 19:338.",
"     </a>",
"    </li>",
"    <li>",
"     Sorkness CA. Beta-adrenergic Agonists. In: Middleton's Allergy: Principles and Practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, Philadelphia 2009. p.1485-503.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/48\">",
"      Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/49\">",
"      Hancox RJ, Sears MR, Taylor DR. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J 1998; 11:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/50\">",
"      Chapman KR, Kesten S, Szalai JP. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 1994; 343:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/51\">",
"      Heino M. Regularly inhaled beta-agonists with steroids are not harmful in stable asthma. J Allergy Clin Immunol 1994; 93:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/52\">",
"      Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/53\">",
"      Haahtela T, J&auml;rvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/54\">",
"      Apter AJ, Reisine ST, Willard A, et al. The effect of inhaled albuterol in moderate to severe asthma. J Allergy Clin Immunol 1996; 98:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/55\">",
"      Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immunol 1989; 84:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/56\">",
"      Simons FE, Soni NR, Watson WT, Becker AB. Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma. J Allergy Clin Immunol 1992; 90:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/57\">",
"      Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/58\">",
"      Aziz I, Hall IP, McFarlane LC, Lipworth BJ. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. J Allergy Clin Immunol 1998; 101:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/59\">",
"      Haney S, Hancox RJ. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med 2005; 99:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/60\">",
"      Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/61\">",
"      O'Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med 1992; 327:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/62\">",
"      Tattersfield AE. Effect of beta-agonists and anticholinergic drugs on bronchial reactivity. Am Rev Respir Dis 1987; 136:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/63\">",
"      Twentyman OP, Higenbottam TW. Controversies in respiratory medicine: regular inhaled beta-agonists--clear clinical benefit or a hazard to health? (1). Beta-agonists can be used safely and beneficially in asthma. Respir Med 1992; 86:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/64\">",
"      Boulet LP, Cartier A, Milot J, et al. Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids. Eur Respir J 1998; 11:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/65\">",
"      Wechsler ME, Castro M, Lehman E, et al. Impact of race on asthma treatment failures in the asthma clinical research network. Am J Respir Crit Care Med 2011; 184:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/66\">",
"      Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/67\">",
"      Gardiner PV, Ward C, Booth H, et al. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994; 150:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/68\">",
"      Li X, Ward C, Thien F, et al. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999; 160:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/69\">",
"      Roberts JA, Bradding P, Britten KM, et al. The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 1999; 14:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/70\">",
"      Nathan RA, Pinnas JL, Schwartz HJ, et al. A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma. Ann Allergy Asthma Immunol 1999; 82:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/71\">",
"      Simons FE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med 1997; 337:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/72\">",
"      O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/73\">",
"      Sorkness CA, Lemanske RF Jr, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007; 119:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/74\">",
"      Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; :CD005533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/75\">",
"      Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005; :CD005535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/76\">",
"      Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen &amp; Hanburys Limited UK Study Group. Lancet 1994; 344:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/77\">",
"      Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/78\">",
"      van der Molen T, Postma DS, Turner MO, et al. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. Thorax 1997; 52:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/79\">",
"      Pauwels RA, L&ouml;fdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/80\">",
"      Wilding P, Clark M, Thompson Coon J, et al. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 1997; 314:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/81\">",
"      Langley SJ, Masterson CM, Batty EP, Woodcock A. Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo. Eur Respir J 1998; 11:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/82\">",
"      Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/83\">",
"      O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/84\">",
"      Gibson PG, Powell H, Ducharme F. Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children. Cochrane Database Syst Rev 2005; :CD005076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/85\">",
"      Mcivor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/86\">",
"      Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/87\">",
"      Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; 362:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/88\">",
"      Bateman ED, Jacques L, Goldfrad C, et al. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 2006; 117:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/89\">",
"      Godard P, Greillier P, Pigearias B, et al. Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomised study. Respir Med 2008; 102:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/90\">",
"      Koenig SM, Ostrom N, Pearlman D, et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are \"stepped-down\". J Asthma 2008; 45:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/91\">",
"      Reddel HK, Gibson PG, Peters MJ, et al. Down-titration from high-dose combination therapy in asthma: Removal of long-acting beta(2)-agonist. Respir Med 2010; 104:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/92\">",
"      Salpeter SR, Wall AJ, Buckley NS. Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events. Am J Med 2010; 123:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/19/16698/abstract/93\">",
"      Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2009; :CD006924.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 557 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16698=[""].join("\n");
var outline_f16_19_16698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Short-acting beta agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Long-acting beta agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Meta-analysis and clinical trial data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Formoterol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - FDA advisory statement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3905123\">",
"      - National Asthma Education and Prevention Program (III)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ASTHMA CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Regular versus as-needed administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intermediate-acting beta agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Long&ndash;acting beta-agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10936292\">",
"      Impact of race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Beta receptor polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      BETA AGONISTS VERSUS INHALED GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Direct comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Monotherapy switch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Glucocorticoid-sparing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Step-up therapy in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3905193\">",
"      - Step-down therapy following establishment of control on combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Potential risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/557\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/557|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/50/1838\" title=\"figure 1\">",
"      Tolerance to chronic B agonist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/25/38302\" title=\"figure 2\">",
"      Persistence of beta agonist effect over time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/33/44563\" title=\"figure 3\">",
"      Stepwise asthma Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/557|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/48/33549\" title=\"table 1\">",
"      Initiating Rx 12 and up",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=related_link\">",
"      Beta agonists in asthma: Acute administration and prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=related_link\">",
"      Beta-2 adrenergic receptor dysfunction and polymorphism in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=related_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=related_link\">",
"      Treatment of moderate persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_19_16699="T cell cytokine profiles";
var content_f16_19_16699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    T cell cytokine secretion profiles",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Th1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IL-2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IL-3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IFN-gamma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TNF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Th2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IL-4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IL-5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IL-6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IL-9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IL-10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IL-13",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Th17",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IL-17",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Treg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TGF-beta",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IL-10",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IFN: interferon; IL: interleukin; TGF: transforming growth factor; TNF: tumor necrosis factor; Th: T helper cell (types 1, 2, and 17); Treg: regulatory T cell.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16699=[""].join("\n");
var outline_f16_19_16699=null;
var title_f16_19_16700="Acute pericarditis etiology";
var content_f16_19_16700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acute pericarditis etiology: Data from published clinical studies with unselected populations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Permanyer-Miralda G. et al.",
"        <br/>",
"        (n = 231)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Zayas R. et al.",
"        <br/>",
"        (n = 100)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Imazio M. et al.",
"        <br/>",
"        (n = 453)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Years",
"       </td>",
"       <td>",
"        1977-1983",
"       </td>",
"       <td>",
"        1991-1993",
"       </td>",
"       <td>",
"        1996-2004",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Location",
"       </td>",
"       <td>",
"        Spain",
"       </td>",
"       <td>",
"        Spain",
"       </td>",
"       <td>",
"        Italy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic",
"       </td>",
"       <td>",
"        199 (86.0 percent)",
"       </td>",
"       <td>",
"        78 (78.0 percent)",
"       </td>",
"       <td>",
"        377 (83.2 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specific etiology",
"       </td>",
"       <td>",
"        32 (14.0 percent)",
"       </td>",
"       <td>",
"        22 (22.0 percent)",
"       </td>",
"       <td>",
"        76 (16.8 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplastic",
"       </td>",
"       <td>",
"        13 (5.6 percent)",
"       </td>",
"       <td>",
"        7 (7.0 percent)",
"       </td>",
"       <td>",
"        23 (5.1 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis",
"       </td>",
"       <td>",
"        9 (3.9 percent)",
"       </td>",
"       <td>",
"        4 (4.0 percent)",
"       </td>",
"       <td>",
"        17 (3.8 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune etiologies",
"       </td>",
"       <td>",
"        4 (1.7 percent)",
"       </td>",
"       <td>",
"        3 (3.0 percent)",
"       </td>",
"       <td>",
"        33 (7.3 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Purulent",
"       </td>",
"       <td>",
"        2 (0.9 percent)",
"       </td>",
"       <td>",
"        1 (1.0 percent)",
"       </td>",
"       <td>",
"        3 (0.7 percent)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Permanyer-Miralda G, Sagrista-Sauleda J, Soler-Soler J. Primary acute pericardial disease: A prospective series of 231 consecutive patients. Am J Cardiol 1985; 56:623; Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. Am J Cardiol 1995; 75:378; Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation 2007; 115:2739.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16700=[""].join("\n");
var outline_f16_19_16700=null;
var title_f16_19_16701="Schematic of gastrointestinal greater nervous system";
var content_f16_19_16701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic of gastrointestinal greater nervous system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 256px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; ENS: enteric nervous system; ANS: autonomic nervous system.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16701=[""].join("\n");
var outline_f16_19_16701=null;
var title_f16_19_16702="Management of immunosuppression in skin cancer";
var content_f16_19_16702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Expert consensus on the management of immunosuppression for specific skin cancer scenarios",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Skin cancer scenario*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Level of reduction of immunosuppression to consider",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Kidney allograft",
"       </td>",
"       <td class=\"subtitle2\">",
"        Heart allograft",
"       </td>",
"       <td class=\"subtitle2\">",
"        Liver allograft",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.",
"       </td>",
"       <td>",
"        No history of actinic keratosis or skin cancer",
"       </td>",
"       <td>",
"        None",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        None",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        None",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2.",
"       </td>",
"       <td>",
"        <p>",
"         History of actinic keratosis",
"        </p>",
"        <ul>",
"         <li>",
"          No risk of mortality",
"         </li>",
"         <li>",
"          Marker for increased skin cancer risk in future",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        None",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.",
"       </td>",
"       <td>",
"        <p>",
"         History of &le;1 NMSC per year",
"        </p>",
"        <ul>",
"         <li>",
"          Negligible risk of mortality, &le;1 minor surgical procedure per year",
"         </li>",
"         <li>",
"          Patients handle this with ease",
"         </li>",
"         <li>",
"          Warning sign of possible future skin cancers",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Mild",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4.",
"       </td>",
"       <td>",
"        <p>",
"         History of 2-5 NMSCs per year",
"        </p>",
"        <ul>",
"         <li>",
"          0-5 percent risk of mortality over 3 years, minor-moderate surgical procedure 2-5 times per year",
"         </li>",
"         <li>",
"          Patients can usually handle this, but it starts to bother them",
"         </li>",
"         <li>",
"          Likelihood of numerous future skin cancers",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Mild",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5.",
"       </td>",
"       <td>",
"        <p>",
"         History of 6-10 NMSCs per year",
"        </p>",
"        <ul>",
"         <li>",
"          1 percent risk of mortality over 3 years, minor-moderate surgical procedure 6-10 times per year",
"         </li>",
"         <li>",
"          Patients can usually handle this, but it bothers them",
"         </li>",
"         <li>",
"          High likelihood of numerous future skin cancers",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Mild",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Mild",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6.",
"       </td>",
"       <td>",
"        <p>",
"         History of 11-25 NMSCs per year",
"        </p>",
"        <ul>",
"         <li>",
"          2 percent risk of mortality over 3 years, minor-moderate surgical procedure 11-25 times per year",
"         </li>",
"         <li>",
"          This level of morbidity causes moderate distress and moderate disfigurement, depression may begin",
"         </li>",
"         <li>",
"          High likelihood of severe future skin cancers",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Mild",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Mild",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7.",
"       </td>",
"       <td>",
"        <p>",
"         History of &gt;25 NMSCs per year",
"        </p>",
"        <ul>",
"         <li>",
"          5 percent risk of mortality over 3 years, moderate-severe surgical procedure &gt;25 times per year",
"         </li>",
"         <li>",
"          This level of morbidity causes severe distress and disfigurement",
"         </li>",
"         <li>",
"          Patients question whether transplant was worth it; depression is common",
"         </li>",
"         <li>",
"          High likelihood of severe and possibly life-threatening future skin cancers",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8.",
"       </td>",
"       <td>",
"        <p>",
"         Individual high-risk skin cancer: 1 percent mortality over 3 years",
"        </p>",
"        <ul>",
"         <li>",
"          Average-risk SCC",
"         </li>",
"         <li>",
"          Cutaneous and oral KS",
"         </li>",
"         <li>",
"          Stage IA melanoma",
"          <sup>",
"           &sect;",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Mild",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9.",
"       </td>",
"       <td>",
"        <p>",
"         Individual high-risk skin cancer: 5 percent mortality over 3 years",
"        </p>",
"        <ul>",
"         <li>",
"          Moderate-risk SCC",
"         </li>",
"         <li>",
"          Stage IB melanoma",
"          <sup>",
"           &sect;",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10.",
"       </td>",
"       <td>",
"        <p>",
"         Individual high-risk skin cancer: 10 percent mortality over 3 years",
"        </p>",
"        <ul>",
"         <li>",
"          High-risk SCC",
"         </li>",
"         <li>",
"          Early Merkel cell carcinoma",
"         </li>",
"         <li>",
"          Stage IIA melanoma",
"          <sup>",
"           &sect;",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11.",
"       </td>",
"       <td>",
"        <p>",
"         Individual high-risk skin cancer: 25 percent mortality over 3 years",
"        </p>",
"        <ul>",
"         <li>",
"          Very high-risk SCC",
"         </li>",
"         <li>",
"          Stage IIB melanoma",
"          <sup>",
"           &sect;",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12.",
"       </td>",
"       <td>",
"        <p>",
"         Individual high-risk skin cancer: 50 percent mortality over 3 years",
"        </p>",
"        <ul>",
"         <li>",
"          Metastatic SCC",
"         </li>",
"         <li>",
"          Stage IIC/III melanoma",
"          <sup>",
"           &sect;",
"          </sup>",
"         </li>",
"         <li>",
"          Aggressive Merkel cell carcinoma",
"         </li>",
"         <li>",
"          Visceral KS",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Severe",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13.",
"       </td>",
"       <td>",
"        <p>",
"         Individual high-risk skin cancer: 90 percent mortality over 3 years",
"        </p>",
"        <ul>",
"         <li>",
"          Untreatable metastatic SCC",
"         </li>",
"         <li>",
"          Stage IV melanoma",
"          <sup>",
"           &sect;",
"          </sup>",
"         </li>",
"         <li>",
"          Metastatic Merkel cell carcinoma",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Severe",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     KS: Kaposi's sarcoma; NMSC: nonmelanoma skin cancer; SCC: squamous cell carcinoma.",
"     <br>",
"      * Estimates of mortality risk are derived from data in immunocompetent patients; risk may be higher in immunosuppressed patients.",
"      <br>",
"       &Delta; Appropriate level of reduction of immunosuppression should be individualized on the basis of specific patient- and tumour-related data.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Unanimous opinion.",
"        <br>",
"         &sect; Melanoma staging derived from the American Joint Commission on Cancer.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Otley CC, Berg D, Ulrich C, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol 2006; 154:395. Copyright &copy; 2006. Reproduced with permission of John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16702=[""].join("\n");
var outline_f16_19_16702=null;
var title_f16_19_16703="Standard cricothyrotomy step one";
var content_f16_19_16703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Standard cricothyrotomy step one",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 320px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFAAXQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pozQaSgBc0ZpKKAFzRmkooAXNGRUcrbY2b0FUhqCcZ4pN2Glc0cijIqgt+hbFOS8QuRS5kFmXc0ZFRCQEZpwYE07iH5ozUZcA0bxRdASZozURkApFmUng0XAmzRkUzcKXIouA7NGaaTSbhRcB+aM0zeKAwNFwH5ozTdw9aM07gOzRmm5pjyqvWlcCXNGarfao/WpFlRvunNF0OxLmjNNyD3opiHZozULyqo5NRG8jB5NK6HYt5ozVVLuNyMGnPcIgyTgUcyCzLGRRmqIv4ixAPSpPtkX96jmQWZazRmqn2yL+9TTfw8/MKOZBZl3NGRVE6hCO/FSwXKTNtQ8jqKLoLMs5FGaQUUxC5ozTaBQA7NFJSigAooooADSUppKACiiigAooooAa43Iw9RiuBnvDDNLE5+4xGK9ANeXeOybLXmxwsyhxXLiZOKUjegrto0o9QyvWrNvfgzL82eK4iG9xnJJ9qvWF3vuEy3IrmhWuzaVOx6Paz7kq4smR7dq56xmPlg5rYtm3Dua7IyuczViZ5DkdzTDPx1ps4I5zxVKRyDjn2JpXEkWZJzjg80Qzg+vtWNNckNtz+NSwT/mPelzF8ptefg81PHJWIbgE89utXLZy2M01LUlxNIyDFRNJ70itkcDmoJiV5PUVTYkiYzYHtSCUcYNUt/PPNIXwKi5VjQEuCDzip43yvtWQspzya07ZsgZq4vUlokcnHFZt/OUHWtYgYrE1cDBFE9AhqZNzesFJB/WptM1QtgFuK5y+m2Oyk8Vl2uomG62biBmub2tmdHJdHqkN0CBjP8AjUjXA5yccVzWm3vmIOc1buLhlB5/GtufQxcdRdTv9gOWxWEmqbpSAx+mao63cu0bYOCK5G11F1v2RycGuedazsbxp6Hollqe5zg8A4NXLu+/dA5OK8707UWWeZSeQ3rWyt+ZIiA2aI1roHTszRTVCLkgtUz6tgHk1w8940eoqCxxnvTbrUsSMC2MVPtilTudo+sYON1Vn1naeXxXCzark/fNU5NVJJ+Y0vbstUT0Qa0TyW/Wuu8EytdW89weRu2g14cupPtzk5HQ/wBK988G2ZsvDllG4xIyb3+p5rfDzc5GNeKjE2qWiiu05AooooASnCm0ooAWiiigAPSkpTSUAAooooAKKKKAENcH8WLIvpcF8g+aBtrH/ZNd6ao6zYJqWl3NpKMrKhH49qyrw54OJpSlyyTPA47jkevrWpospa6OeT2rAmikt7iWCUESRMVYfSr+hT7LnJPJrxKb95HpTXunpumsxQCt+zk5A6VyukzAjAIJFdBAxBHoe9epBnBJGlLytZd6xVGrSU7lrL1JcIxq5bEx3OYu7xllxyOfWrmnzh+pGa5/VWYXKdRk1p6PzKBmuaMtbG7Wh0UCFiPSta1j74FVbSPIHpWtbIAPaumMTCTHJGdtQ3UZ256mrwAqvc8IRWkloQmZDZDUmTzjiiRsE5qFpBkDp6ZrB7mqJM9OlXbSfaQDWeDn0p+7AHamnYGrmu10uwnNY2pzZQnPNBkxkfjWZrE4WBupIFE56BGOpyGq3g+0MB64rDu7lYZ42ck5PWlv5ibw9uao66jfZ4XU8Bq86cup2RR3mgXWQoGcfWuoIEkZ57V5voFyVChjXoGnTB4xiuqlK6MKisynfaeHjJxzXmWuIbPU2KjABr2iWPMecV5f48tdk5cfWoxELK5VKV3YxJZTHeRvn5ZRyPete2uCFx+lc1eb5NNSVc7ojnir+m3P2i3STcB61yqVmbNXQ3V5ALyMmszVbzyrhl6EgYq1rDEPG3v1rnfE0xW7ixxujzSky4LUGuyzY75oSUl8sevas+A7yD29e1Xoxn3JqLmtjovCdodU8Q6dZBeJJQWHsOTX01GoRVRRgKMCvHPgbo5lu7vVpE+SMeTET6969lyAOa9fBwtT5n1PMxUrzt2FopODS967DmCiiigApRSZoFAC0UUUABpKU0lABRRRQAUUUUAFIelLQaAPGvi3pDafq0epQofs91xIR0Vx/jXEwzFP3i9e5r6I8RaZbaxpFzZ3ib4nQ/UEdCK+ZopfLnliY5MTsnPXAOK8bF0vZz5lsz0sPPnhZ9D0vw3frKi4PUfjXbW0mUBPA7V45oVzJbXIKHKmvT9KuvNiQseQOla0J3RjVjZnUWh3cdRVbVo9sDkUWUo39an1Nd1sw9q690c+zPLPELlCH/unk+laPhq4Em1s5z3ql4ljDb15II6Vj+Db0xXb2czEspyD7VwqVp2Otq8T2CxYYFa8LDArnLCZSg61pQzY4ya7ouxyyRsZGM1TvHG04oSb5ODzVS8kJ4rSUtCYopzHA9KyprjDY96u3LZU9cVg3cgXduOK5pM2ijZtptxz3q4D8uOtcfHqqxSKpJrobO8EyZFEZJjcbFiUsPQCsnUUaSMqa2eH47daZJCrD3pyVxJ2PMdZtDDJuI6VWuIxeaW4X76jPvXa6/YeZA/y5wK4i1kNvcNFIMA8YrinGzszoi7q5U0m82Fevvmu/wBCvt6rjHvzXl+rK+nakHU/6PIc/Q113h69C7R2NKjOzsOpG6uepwsJIPw5rhvHVr5kDMAc5rrNHnEiYznNZviqAywPgc4rsqrmgc0HaR5Rp674Z4W+6QRVXRW2xSxf3WqyhNtqrKehODms6GT7Pq1xCejNmvObtY7Cxqb5UZPINc54qOJbJiTkrjpW9qZG0dOv41geLGAexT0Unmom9GaU9yKzGQpzjNaFpDNdXMNtbrmWZwiKB3NZduyqgJ49q9g+BGgQX0txr1x8zwOYYUPQHu31q6NJ1JqIVans4uR6t4S0aPQtBtbGPG6NcufVj1NbBGRSClr30klZHjt3d2FFFFMQUUUUAFAooHWgBaKKKAA9KSlNJQAUUUUAJS0CigAooooAa4yCPXivknWEa08RarEMZW5f+dfW57V8s+PIDD4y1hRwpnJrz8ftFnbg92ibQbz/AEuMNznivUtLB2qV7814hZStDcI542sDXt3hiTzbWMjByorlwzu7GtdW1Oo04neOlal8C1sfpWdZnDjA4rVn5t278V6MNrHE9zzbxHCBu4rzrULs6Xq0N3j93nD/AEr1XxBGTGxry/xHbC4hbIyQa87EKzujspO61PUdBvkubaN0JKsBg10kbfICDXjXwx1iRQ+nzPloj8ufSvXbR/MiBrqpTUldGFSPKzXtjuTmmXCZHOKSybIPNWLgfJ+FdG6Mepz98MA4rmNXkxG/r6V1GosMN9K4jU5RukXPHpXLVdjogjiNQ1g2t4A5K8/Wu58M6otxGjB88c15V4g2DVJBLwMZ+tXfCWsCyvEiZv3TnAJ7GuOlVcZanROF0e8W04bHP0NaEYBIrk9KvfMUHdkeldLZybgtejB3OSSsSX1qJYnGO1eb+I9NaCUug6c16uq71rA17ThLE/HOKmtT5lcdOdmeT3sX22zaNj8wHB96peHLxlBil4kjPNad/E1peMCCBnpXP6sPsN+t4mfLf72K816O51rVWPYfDN4GCAkVt6tEJLcnjpXnXhPUd5RgwKnkV6SrC4s8jHTrXo0pc8DkmuWVzxjxJCbbUg46Zrn9Vk8vWIpBwsi9a7Tx1CVldvTtXDa3h7C2uM48psEj0rzqmjZ1x1Q/V7jAQHGT1Arl9Yvftd/nO5Y1CLVzVL0NEzKThR1NYVv855J55NZydzaCsaULkjGeevNfSHwDg8rwIkmDmWd2P5184wR5jGfTPFfUfwfg+z/D/TFIxuUt+ZrvwC95+hzYx+4l5naClpKWvWPNCgUUUAFFFFABQOtFAoAWiiigAPSkpTSUAFFFFABRRRQAUUUUAIa+cPiXbf8AFcarjGGcN+lfSFeA/EuM/wDCbX/YFVNcOP8AgXqdeEfvM4ZrYlc9QK9T8ATl7KNT1UYNcGIcEkDg11/gZxGzRg4571wUG1I6q2sT0y24cY6ZrVmH7g+9ZFoeVIPNa83/AB79a9SGx50tzkdbjLI3Fed6tAN8n0r0nVhuBxn6VweuIsYkduOK48QjqpM8xF82i66t6HCorYck8YzX0F4bv0u7KJww+YA/nXy78R5fsnh29mlO1rg+XGO55617J8ENaGreEdPmLLvEYjfnoV4rPDJqN+lyq7Tdj2C3f5versvMWevFZVu2SCK0lO5B34r0I7HIzndSyN/sK4DVpCtwwPU969D1ZSN2BXmnihCrMR25zXJiNDopanlnxf1GbRoLS6toVdpyUDN0UivOrDWded1uDdFyDuCbRivSvi5EbzwRFPjLW1yrNx2Ncj4bt1uosEDntXO3GFO6V2zoV2z3L4b+IF1bSIJTgSgbXX+6RXpOnXGSCSMV86+D7l/D+tfMSlpcfK/oD617dpl2GVWRsitaNS6MakLM760lBWpLmFZU471j2E25V55rbhlDrgda7k7nM1Y8z8Y6S3zMq8g9q4iZRcQyW0oX05r3HW7Fbq3bjJ715B4h09rO6ZwD1rgxFPldzqpT5kczoV8+mXzWk5OA3yn2r2vw9qCzWaqWzx614nrkAnhS7hB86I8kdxXU+DNX326AuAR2qMPU5HZlVY8yubXj+ISK3AJNeaawuzQZlYYIYAV6V4gmWS3JZsjHWvIvGuqJHbpbx/ec5GKivbmuVSTasc/qF2JY4rWHnbzIfU+lWbOH5Qdv4VmadbksCeCTzXSQRbUB/hFc61OlaIVIysT5HbrX1b8P4/K8GaQn/Tupr5Z2fIeP/r19X+FEMfhnTE6EW6fyr0sAtZHDjHojYopAaWvUOAKKKKACiiigAoFFAoAWiiigANJSmkoAKKKKACiiigAooo70AFeE/EoY8a3Y7FFr3Y14b8Tf+R0uAf8AnmtcOP8AgXqdWF+JmDCoaPLCtzw0ojvMY61j2g+Tv9PStnS22XkfuMV51LSSZ1VNUek6cRhTmtqck2oxXOaWwKL/ADrogC9r9K9anscEtzm9TH3j7V59r8DSyEu2yJOvPWvRtXACnsPWvNPEvnXLPDCP3fdq5MRojoonhvxit31GxW7hLeTZybSg6YPeun/Zn1FoYL6xYghXEqD0z1rP8YhIPDutRznCbBj3OeKy/gNdi28QBCf9dFg/hUUJt0rPozWpFXufXlnLuVelbFvyuK5zSpA0KEYPHNdBZtleetdsGcckZ+rpwfevN/FER2seo9K9R1SPKVwfiGDer96wxEdDWizyrVrFtT8MatZY+Z4mZR7jmvNPA8m10HcfKR6Yr2K3b7PqTKxGGNeTT2v9jeMr+1xhfNMi+4bmuFaxsda3O+uNPS5tAQBk9/euh8HawzJ9ln4nh45/iHrVHQiJ7JWIHFV7+CS0uFvbcfvEbkeo71ajye8hP3tD2DSLotjn5fauntZOAa8t8Nayk8Ubo4KnqM/dPoa9AsLkOgIrspTuclSNjoFw4weQeDXD+M9IyjkLnuPeuytWLL83WjVbZbqxbI5Fa1Ic8bGcJcrPnxojE7RScKcjmsOxlfSdXMLn9053Kc9a7TxfYG2uC6ggZrjNeQT6eJgMSQnOe9eTP3Wd8dUbOu6vLcRJBb5APU15NezPe6xMzHhG8tefSu1u9SS10OW4cqCifKPVj0ri9EhMnzMDknLZqJSbV2aQVjd0y25BI6DAzW0i7EOcUyyhCKOKsyAYOOnepiWQ4JUDoCRn86+stEULo1ko4AhT+VfKCKS6f7w4/GvrPTBjTrUY6RL/ACr1MB9r5HBjOhaFLSA0teicQUUUUwCiiigAoFFAoAWiiigANIaU0lABRRQKACiiigAooooADXhvxMJPjS429kTPNe5GvCfiO+/xtejptVRXDjvgXqdWF+Jmbag44x78VcMhiRZVHCnt6VVtTjHH41oxquz5ulebE62df4duxLEh6g9K7HT5AQVY8GvJ9FumsL4Qk/un+4ew9q9DsLkMgPUV6VCpdHFUhZjdejXaydulcPqMSxIQvpXd6kvmRk4rh9dO2Nx37YqK6KpnkHi7TYL2O7guhmGQ87T0PrXC+GbObwr41sYpyfJdx5ch6Opr029tzPJIg+bGSa4/xgpbSLCcY822uNoPfFcFKbTa6HY1c+l/D8wa2THauntHy3HFed/D+++2aPaS5BLRjP1rv7RvumvSpPQ4Zou3qFoCTya4rWYzsYEV3ZG6E89RXJa1GPmqqquhU3qeS+IYhDdqwHevPPibB5eq6XqKnAlQxP8AUdK9V8Vw8EjtXn3xAtftnhB5k/1lo4kH0715i0k0d8djT8DXHnaeVzyDXS3cYeA8ZPvXnnw5vAYNu73xXpCP5kYx34PtXVT95WM5aM5C4u5NB1AXCZ+zSHEqDp9RXqvhTWUuYU2uGRhkEdxXmviS1eezkRlww9ay/h7rMljqQsJHby3OY8nofSs1enIc1zRufTljLnBzxWq7qljI24civP4NY+z2yluDVW+8St5JCsfpXZ7ZRRy+ybZnePpowjdM15mrGW2uU6gqTiug1+ee83uckelYFm2GlTG0spAP4V5lWXNK52QVlY851q+e9uYbFD+6gOWx/E3vXQ6FafKpxx1rl9Kt2N3L5md3mNlvfNeg6RCRGCOfpWU90jZaF5IwmFxxTJzsGCcZ4q0cbffufSqs65yaEBGgPnRg/wB9f519aaeMWFsP+mS/yr5MjH7yPr99ePTmvrPTv+PC2/65L/KvUwG0vkcOM6FiiiivQOIKKKKYBRRRQAUopKB1oAWiiigANJSmkoAKKKKACiiigAooooADXgvxCOfGuoY5PyjH4V71XgXjkk+NNTOf4x/KuHHv3F6nVhPiZUtDjGTxWpCBtI61k2mSeMFa1rblcA4rzYnXIW5g8xOOGHQ+hra8M6swb7PcHEinH1rM29f61WmBjdZ0yHQ547itYTcHczlFSVj0i5nDW56ZArzvxRMc+Uh/eN+ldDZXxurRTu6isltHmvNYSUn93nJreq3JJIzglHc5qHTjbWjM43Fs5Pc15h43YQ21rBx+8uC3HtXu3imFbO1fbhQB3rwLxwxm13To85CoWxn1Nck4cskjog7q56h8J70RWy27E4TBB7c17LaFWjBHevnzwnI1ndW8nIjOFaveNJmMlvGc5BFdtHY5qq1udLaHcAO1YevwkF8Ctexblaj1qAOCRnOK6ZK8TBOzPJPEsPmRHPFcZ9nFzp17ZuN3mxsuD9K9G8RWrYf5fWvPwPJvjxXlVVaR3U3dHlvgS4azv5LaQ4ZGKY9wa9w0maCC1WSfAyM9OteKX9uNM8b3aEYWRxKh+td8moF7ZQTwBgV1UNWFRGr4h1GOeNxGgA96831A/Zb5Lu3YK0Th/wBa6iZzICDmsHU4wUfIGK1r07aoUH0PZdGv4tQ06GUMCroDVm4t4QvABrzT4carthazd/mhPAJ7V6PM48oMOcjrXJe6E1ZmfcxqVKADB61yd9CIL3jAGeuK6oNljgZH8q57XlInViPbOawn3NInntrZ+Tql0mOBKTXaadGBCoPA/nWRcW3l6zKxH3wGHFdFZIvlDI6Diseps9iOVfm4xmqkgx/Fn2q9cctjPFUZTg8fjTBEaDDpx/EP519YaYc6bant5S/yr5RGODyRkH9a+q9FO7SLIgdYV/lXqZe/i+RxYzoXDSiiivROEKKKKYBRRRQAUopKUUAFFFFAAaSlPSkoAKBRRQAUUUUAFFFFAAa8A8cEN401Ug8CQDj6V7+a+evFzb/F2pnuZcVwY/4F6nVhN2NtADj0xWvAFxx9ayLZTwBWzagFOBzXnxOqRKBnp+NMmXjmrCKDnI/KorgZIxVWJuRaKzpdNAT8ucrXf6XbqkW7aOBXnUMvkahC3TnBJru7bUVFseR0rpw7VtTKqtdDjfifc7LVlUgbu9eGeJYS/im0/iBhFeo/Em9E21QxLFsVwOpW4l8S2qnrHAMn61zVHzVGdFNWidNp0JNj05A/KvUPBN/9p0yME/Mvyn8K4fTbYC2C4x8taPg65Nnq8tsT8jncv1rtS5UmYT1PX7NuV71ozRCdO3IrnYboIgO7nGaV9bVAfn/Wt1NW1OZxbehX8R2UaRvvIzivEfEUqW98CnQnrXpfinXVeJsPnjtXj2tzi6uCzcAHvXnYuUb6HZQi0tTmviCgGraZeJwJE2E+4q/prFo1bORVLxqc6Tp8h5KTYq1oSM0SYxzWmEbuXU2NpUGzJxWXqUP7tjt49TXQ28ACfMM5qrqcACcA4xXoVVdGMXqcR4duntPE8Y5CyKQ2K9j02+EtsI3bn1z1ryLRIll8c2sUgyCG9u1ehNazWsmYWyh7elePJtO5u1dnRKFHI5rF8QFfLBGM0+C5lJIcdKo6izTOqYySfwFRJ3QJWMy+Gb2FupKDNa1sCEGetZCyi6vmdfmRfkX8K2FyIwOBms1uavRIhuuWyOKz5tvUj8qvXDfNg+nWqMmTnHFA0KvC5yCOK+qPD/OiWB/6Yr/KvlVeF45NfU/hs50DT/XyF/lXpYDeRxYzZGnRSClr0zhCiiigAopKWgApRSUooAKKKKAA0lKaSgAooooAKKKKACiiigBK+efFX/I16nnp5xr6Hr548SDHivVF/wCm5rgx/wAMTrwm7HWYwQfQVt2YygI/Wsa1APTjB4rYtDjjFefA6ZFxBg4HSo5l+U56GpEJ4JAxTZhla1IOc1iTySHBOVOamHieKC1Ad8HGcUuq2wdGJ5BFcJq8t1axOIdmR0LLnFYupybGihzEeuapHJdm+1KXyrcf6tD1c+gFZ2gTSX+py3sqgGQ8D+6B0FcdcQz3OoGS7keWQnqx6fQV3nh23KBDjnFOjaUy5qyPRdOj/wBH5HUVFOhttRguE42sASasaU2YgehqzeQ+bEQelery3Vjjvqb0s7y22Ubtxiuc1CS5VsBjir2m3DCEK3UcHNS3kYfDAAg9645pspOxylzC8o+diST3NYGsaesalxnPU+9d01rnoDisHxHZstsxrmnDS5tGV3Y818YAHRbUk/8ALcVqeHE/0ZOD9KpeKYt2k2y9QZxWvokZWFVHp9K3waCpsb8a4XAH1qnqABh6jmrq5A4x06VR1Jl8s54GK9KS0Odbnm/2waf4406djtTzgjE9geK9qCI5ZdwwDXz743iczFoiAwO4H3Fdh4P8fWeo2sVtqdz9i1FVCM8n3JMdDnsa82UG43Wtjd7noF/dpbghVHoB3rjtZ1lknaztiTO/+sf+4PQVPrmt2tlHvguY7u8cYjRDkL7muf0a1eWdppSTI5yxPUmuOUmjaMTqdGh2wIG4GK2sfKOfxqtp8QSJcjNWzkKQc/hSirIHqZ87NvOQeOKps3zHrVy5XDMQcA1SfsR16Z9KCkPTG0kDoK+pvC5z4d04kf8ALBf5V8tJypwea+pPC5/4p3Ts/wDPBf5V6WAesvkcWM2Rq0UUV6ZwhRRRQAUUUlAC0CilFABRRRQAHpSUppKACiig0AJS0gpaACiiigBDXzz4p48V6n1/1xr6GNfPni1Qvi7Uxz/rq4Mf8KOvCbsLPBwPbrWzAMAEdv1rHtDyOeO1bFuQNoPWvPgdMi7H93rmkkxtAOc+lCdc9qHwOR1rUzKN1FuBrmtW0/zQykDPpXVuMqQeDVC4jGDxWc43NIs8nvdDdb4bVO3PPaul0y0Mca8fhW/PZqzgkDPrU6Wi8BeuO3etcHT95hVnoP0slNoFa7DKjHFZcMLIeO3U1oqzbAGNeokcrIZG8oh1529a0LS4jlj5xx1rOly3GMcVkyyTWUnGfLbofSuXEx5XzouGuh1NzcRIAFxz2rlPE9zugPTB45qrda0qMN27P86zLi6e+ycEIOea4alVNaG0IWZgeIY/MsLNehM2eK1dNTaqnGOKqTR/2jqUUcHzQwd+xauhgsyigdCPUV14OFo3ZNV62Gu22PkYrJvCZc4HHrW1JASO9Rm0ATJ6V2syR5P4ptmE2DzmubtdFSWQnYpXNdz4sizd7e2fzo0qyBGSAK8ivOVOVo9TsglJalHSdKWPaAoArrdMswhGO/SnWdmAAMfjWvbRBQCBgj2rks27stvoi3CgEQGO1EmNowOakQZj65NRuTs4qyTNuxhj3zVOQE8HkGrlz1IHBqo3t1/SkikPixtIKn3NfU3h0BdC08Dp5K/yr5bhyF57kfzr6o0QbdIsh6Qr/KvRy/eRxYzoXaWk7c0teocIUUUUAFIDS0lAC0CigUALRRRQAGkpTTaAFooooAKSlpKAFoopO9ABXgXjXjxjqf8A10B/SvfjXgvjxQnjTUgB1ZT+lcGP+Bep14T4mVrQHYCf0rXtc4HTNZFrwBg/nWxakfLkVwROmRdj4Ge9K/OM0xCN2R/KnydM1qjMryDGSRVdgCcnP0q254571U5Byec1EikVJowcDHPXFNfIiLJnK8nFTyA560iA+Y6jkMmTxW+Edqlu4qnwkthd214o3Ha/Q1NdTWlv8qyGRv7qjOK5/RbBZbm6kLHbu2gA/rV61txNeMtuoWOP5R6k+td6mnJxXQwcbK5I5upmAgi2KehNRrYajL5yMA3lnlCO1dBa2cqXG+Vh5YTge9adsoN07jqyjI9aUpPYEzzi60lRJtkJjf3HFYup2AI8tZpJTnAVRgV7Ff2MEuGeMGsY2MA1Enykwi8ccZrnVKnvbUtVGec6dbXNnwsWMdsVsfbWjYLdQbSe9b14kcUhLAER5duO9UrqzaeaPIBTbvJ9/Stoy8hMSOOzlRv3wQ+9ZWqXlvGn2eA75G44qO/UQ3GwcKfTsapRW6Jq8ZVcbwc5p+0XPyPcfL7vMclr1uWvlUjlRk4rQ0y32xgMMVpXFqklzMz4+9jPpUkcQQYPT19a8rFK9V3Oqm/dEgXnDcN0q6ikDqQajjA6Ywfap16cnNY2KY8KAn3ce9Ry/cNTHsD3qF/8+1JjRmXJANVGBDAflVy6zyD07D1qnJnPekiie1ILooHVlHP1r6r05dlhbL6RqP0r5W0zLXlsuMkyoB7819W2wxBEMdEA/SvUwC+JnBjOhLRRRXonEFFFFABRRRQAUCilFABRRRQAHpSUppKAEopaKACkpaKACkpaKAA14b8SU8rxrdEfxIpr3E14t8VYyni8Nj70CnNcWO/hr1OnC/GzFtjkDpWvbfd5FYtpwARj3rZtjkD9K8yB2SLsXOe1SPjA5qOP7x6U9hk+1bLYyI2JweardeetWm5BBHFVyMcZqWUivICG46U6xjaa4mwvITApHBLUltdNYXHmN80Z4Pt71thmlPUVS7iU9GVoxcqfv7z8tW9L+SLjO7JJp8Eto9/JNuG1vyzS2yhQ20grniu+EOWUn3MJO6NSG5YoY35B4FWdPkdLl/MOQVwKyVlGcE496v2zLMhjLYbsR2q5RuiUbQYSQ5HNZAw8spB69qmQvDbCMqWZQeR3rPCzghsbOOc1jylFCVDLNeLIMBmCgeorO1e+W0gWGEkHGDg1c1G8S2jYZyx71xV/dNPMcEnmtYxH5kt5c+YqsCfvVfsIGuL6IoMleSfSs6yULd25nG5dwJHY10K6pBatNNBHjjhQKzqQvUjLtcpO0WjBu1Ed9cxnqDnFRMMY5PNIWeSSWeXHmSnJ9hQMsB6V5mIalUbR1QVkTRgYHHbrU8bDGG4/rVePIGM1KMk8YxWBRYJyvFQSnCn0p4ORnJ4FROSFJ65pMZm3LZY7uAOaovJk+g7VduiNwzxmqMoz6fhSWhRp+Hk83W9OQdWuEAx1619VqMAD0GK+X/AsPneL9IiKknzgxA9q+oe9etgF7rZ52MfvIWiig13nIFFFFABRRRQAUDrRQOtAC0UUUAB6UlKaSgApKWkoAWiiigAooooAQ1498YY9niSxfJ+e3I/I17DXk3xsUJf6RIeAQy5rkxq/dM6MN/EOPtX+UHv0ratvu/hWDZ/d9a27YknbXlRO2RowEsM44HFSMOg/WorfOR0qZjzzWyMiFwTULKcY596sPwvIqFjk8dB60mURN04qFsDPAJPUVPIMcDmomAxg4zUFEMSqF2BQEPBHamW8qWu6NiFCHue1S9fWobuyS7zuJ3AdPWunDVuWVpdTOcbol8+KTJicMD702LUPKcbmx71FbaQHtZCgIkAyAKQ6JeyxI0JD5GQrda9JTT3MGjVj1wKMBlI+tUtR10Fcbh+FYk2l34fatq7P32mqv9nXDoS8exV5JY0WiNFfUbp7xztJA9c1XgESON7KD71YNkSsWScuPpxUP2ESStGMbQetJzRdiZsfaUC8heTinklmyxyPQ0xIjHnnOeM0vykHjI6H1rysTV9pL3djopx5URyHDYH51EWx9w84p8u0MCOlNIyc+neuVmo6Ikrhj3qwhyeOvb3qGIEBSO471NCrB+mB+tIRPjCjpmoJv9V2q4UGzPQ+lVLhSMmgZkXY3ScHHHIqk5JGFH41cufvnGPc1W+pxSRR1fwpg8zx1ppJzt3Mfyr6T714B8E4DL4yL44igY5+te/ivZwStTv5nmYt/vBaKKK7DmCiiigAzRRRQAUCigUALRRRQAGkpT0pKACiiigAooooAKDRRQAmea8y+OEOdL02fbnZPtJ+or0zAzXnPxukA0GyizhnuAR+ArmxX8KRvh/4iPNrEjaoX9K6C1A2jvWBpyEBSM10VmmQOwPbFeRBHdIvQKP4emO9SsvHrmnQICB0IqVk4wBz3rZGRTcVG4x06GrEynvVc57nipZSIn9PWoXGRjGTUz570zgjipYyBehycYp6kcnrTCQMlsHBpcgKe2aEM0dKuVZnXBBHPI6ite3AhhDJjywcisOymUQKpAIxWjBJbCPaWZFPB56V67hY5LmlKI1UycAgda5q/gLLFEg+eduntVy7aMRGJbhzH2Ga5nVb6SJi6yv5irtVs9BSUGUh11CuZp1wIYv3a57msIXK+YyActxk1lyXszN5Zlby87tueM1ZJJWE56n0pVKdoPU0i9S0Rkniom96kPTI/Sq7t8pBOPevFZ1jHbpgD8aAcYGeMVGTzgjBqVQO/T+dSMsQqFUHrmrUQJYHBFQQID2zVyFM470xEmMqf51Vnj+WtB1IT/61VJ1LLj9KbRKMG4PLZ5aqMg6k9K0rqMh24x+FZ8qkA56VKND0/wCAUAfVdTuD1jjVR+Ne2968Z/Z6cGTWkJ+b5Dj2r2evcwi/dI8rEfxGFFFFdJgFFFFABRRRQAUopKUUAFFFFAAaSlNJQAUUUUAFFFFABRSZooAK8Q+LuqLf+KoLKJw0VmnzAH+M16F8Q/F8HhjSm2Mr6jKMQxZ5/wB4+1eA2Ust1dyT3DF5pW3u57k152OrK3s0duFp299nT6euFAFbloBxn0rHsRtAOOPatu2IwOcn0rhgbyNG3GODUr8DnOaigbIH8qmc54b0rdbGRUm7c8VUY/N9atSnIzxjpVNzhz69aiRaGMevGRTN3FDsOuageTArMoQt8+PenFhu7kd6jBG446Upb6DHakMqS3E9lKylS8J5XHarEeqxZUSBlPuKvWCxXMTGQAEEKoPetueztRCm6FTsIzxXsRm1Fc25yytfQ5WTVbY5CyLWHq99DMjAEZ7V302iWEjsRGoLDgBelYd7pFvHFPsQZyADiq9ouwJHnYG+UsiM30FaFuruVZ1CqnQeprfsraBbe7yo3o2PoKzJ5YjKIlIyM8VjiKj9m7I1pr3tSOTBBHSqxHGDxippz8v86qBjgnPtzXkM60L/ABHHJFWFTIGOvvVeMAnkn2q7CmOAODU2As2ozgkY9quovzdccdfSobZBxjmrgXtjmqSIbERCBhnLH3qGYckjn2q6EDcEYHrUUqY+n0psRz99Hg5IOMdaxrtQOBn61096nU4yKxr6A4PHap2NEzoPgvrS6X4z+zTOBFfJ5eTx8w6V9GivjmTfbTRzRMVljYMjDsR0NfSXwx8ZQ+K9HUSsE1K3AWeP1/2h7GvVwNVOPI+hw4uk786O1oozRXecQUUUUAFFFFABQKKBQAtFFFAAaSlNJQAUUUlACmikYgDJ6VyniHxtp2lFooT9quv7kZ4B9zUTnGCvJlRg5OyOpdlRSzEKo5JJwBXn3jL4k2mmJJb6OBd3n3d//LND9e9cT4h8SavrhIuJvKtj0hi4GPc965S6iAUhRxmvNr457U/vO2lhUtZlPVb661W/kvNQlM1zIeSew9B6Ve0mErjjjvVSKDe/I5rd06ELtUZrhTbd2dcrWNW0XIAA47ZrVt1+YelU4IsbeSPatKCI7gccVrAwkWoWCkc1O5yTzUaICc4qXyxit0jNlSY/IQRWfMDkEE5rWniBBxzxWfNHiomiosoTY9OlV2J61anUllOD9M1XkQ/T8ayaNERA8ZFLv+UnvSbQvJzimkdxUoZo2Fwot0UqG71rRz27xGMyuueozXIOtzbEtbjdGedvpUg1GVB+9gcD1Ar2k4zSaORxaZ0tzOYTuS7YfWud1jUH8lkNwSv3uBj9ahn1ONxtwfpisrUZVnj+XdkdgKrlQIyftsr3cjNIx3/e96nLgTx5649KrRwsWJWMnnrirMUMm7zJRhscD0FZ4iSVNmkF7xI7bhwMj0qAJubkVaKnHH44FOhhJcHr6V4mp2CQxKSMCr1tHkZ5BHrRFB8wPNX44MABR9KaRLYkMe1QQMkmrSKT1p8MZxjvUqQnPoPeqsRcYRhfX604oGGO+KsJEQvrS+X14waqxNzHuIR15x7Vk3sWYySCPauiuIyM8HNZt0mUHb1FQ0aJnHX0R5A4z19ar6Lqt7oeqx32mytDcRnGR0cehHcVtX1sdx2j9OlYk8BPTpUxbi7o00asz6G8D/EjTtfRLe/22Oo4wUc/K/up/pXfA5HtXx5ApKgEHOeD3r0Xwh471fQ1SG4c31moxskPzL9Gr06OOW1T7zhq4XrA9/zRXN+GfGOk6+qrbzeVc94JeG/D1rpK74yUldM4nFxdmFFFFUIKUUlA60ALRRRQAGkpTTHZUQsxAUdSaAFNY+ueILLSUxKxkmPSJOSfr6VQ1jWppQ0On/KOhl7/AIVzDaYXcu5LOerE8muepWa0gbQpreRR17xBqur5Tf8AZrY/8s4zgke5rDj0888de9dYum4PA4p/9m8Zwa4JUpzd5M6VNRVkcfJZkAjb/wDXrMuLFs42nHXpXfyabnPHaq7aYO6nGelR9XZSqnGW2mtxxitazsQBwPqK6JNK44HNWYdNKk44z2qlQYnVuZEdrjA9KvwwHqBz0rRWzw3SrEdpnoK1jRsZuoZscJ3VMbfoefWtJLQjH9KeLbI46VoqZDmZDQZyexqpNbkgkda6P7MQOn41E1md3TrQ6VxqZyc1qT25qpLbHnjLV18tj1GKrSafkVi6JoqhyZtjgDHNRtbkH1P0rpzpx9Dj1pj6dzwKj2LK9ojK06APGVlUA52qvf61pzWUQjVCg5PFW49PGxSQAR371ZWyZzu8w5HSu/2dlZGDnfUyrnSrVyh8sdMEYrGuNMhgwwTChsV1r28q9ZFPHcVn3VrJJFIrFdrc/ShQYKRx/wDZ6Q3hDjhgSDWdc2+Zwq4yARjFdRNYTzMoLltnFOOk7pE+QfWpq0eaDTNIVLM5RbJsc85FWbexYYIHeuqTSTn7vtkircOk7eo+tcPsGauqcvFZtu5GADV1bQ8YXvXQrppz05qYaf04pqgS6pzyWxwMcCpktuOhzW8mn+nSnLYk/T0qlRZPtDFFtgDGMe9IYDyK3zZZHI+tNey+TgCq9kHOctcW5IBrPubUsvHp1FdhJZEnoKry6dkfdrN0WUqhwNzYs2eD71j3GnFmwBXpUulk9F4qlLoxb+EZqHQZoqp52NPKnOcY4rWt7LKKPauqOiEAZFWYNKweVFCoMHVORSwfcrqSjjoy8EV2XhzxpqmlhIL4G9tl4yfvgfXvU66TjBC5FOOj5/grWnCdPWJnKUZaSPQtE12x1iEPaS/P3jbhh+Faua8ph0x4XEkBaORTwy8EV1+h65MAIdTXLDgSj+td9OrfSWhyTppaxOnoHWmoyuAykEHoRTh1rcyFooooARuhrK1Avdfu48iIdT6mtVlDDB6U3yk9KmSb0GnYwY9NGemDTjp3PQ1uhFHal2j0qfZj5jCFj6LzT/7P46da2di+lLtHpR7NBzMw/wCzeelJ/ZncgVu7RRtFHs0HMzFGnD+7SjTxzx+lbO0UbR6U+RC5mZAseTgAU5bPHatXaKNoo5AuzO+yegxR9l9ua0cCgqD2o5AuZ62/Xj+tIbTI6Vo7RRgUcgXZmNZ9Kjewz2wa2MCkwKOQfMzDGn+1NOm85xW9tHpS4FL2aDmZhDT2AxilWx9RW5gUYFVYVzCfT89v0qB9MzkbeK6PaPSjaPSnYLnLf2SSeFH5U5dKOQSoFdPtHpRtX0pNXHzM51dMJ7cVINO/2a3to9KNo9KnkQczMQaf7c/SnfYAe3FbO0elG0elHs0HMzHOn8dKVbIDt+Na+0elG0elPkDmZkmyGfu002ORjFbOBSYHpRyBzMw20/8A2ahfTuOF/Sui2j0o2j0pezQ+dnNjTSexBqNtNJY/L+ldRtX0o2L6Cl7NBzs5V9KJAO3mnppZUg4+tdPsX0o2r6U/ZoOdnPppvQEU8ab7cVu7R6UFQe1Hs0LmZiDThjpmgaaOpAz7Vt7RRtHpT5EHMzPtI3tvlXJTuK0FORmjaPSlxVJWJCiiimB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <font class=\"red\" color=\"black\">",
"     <font color=\"black\">",
"      Immobilize the larynx and palpate the cricothyroid membrane with the index finger of the non-dominant hand.",
"     </font>",
"    </font>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &copy;2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_19_16703=[""].join("\n");
var outline_f16_19_16703=null;
